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Please find attached a manuscript entitled ‘Arabino Mycolates from 
Synthetic Mycolic Acids’. Much is known about trehalose and 
glucose esters of mycolic acids, but there is relatively little in the 
literature or simple arabinose mycolates, even though penta-
arabinose tetramycolates are major components of the cell walls of 
mycobacteria. We report here the first synthesis of arabino 
mycolates based on unique synthetic mycolic acids and some 
preliminary data which show that these molecules are of some 
potential in the diagnosis of TB.   
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1. Introduction 
The mycobacterial cell wall has a complex structure made up of 
lipids, glycolipids, polysaccharides and proteins.
1 
There are four 
major components: peptidoglycan (PG), mycolyl-arabinogalactan 
(mAG), lipoarabinomannan (LAM) and extractable lipids.
2 
The 
mycolyl-arabinogalactan (mAG) complex is the largest 
component structure and acts as a permeability barrier that 
prevents passage of antibiotics. It forms from cross bonding 
between both D-arabinofuranosyl (Araf) and-galactofuranosyl 
(Galf ) with a long chain (C70-C90), α-alkyl branched β-
hydroxylated fatty acid, ‘mycolic acid’; carbohydrate (Araf) and 
(Galf) are bound to peptidoglycan in the cell wall by an α-L-
rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-α-D-gluco-
pyranosyl phosphate disaccharide. The galactan part is linear and 
composed of alternating β-(1→5) and β-(1→6) galactofuran 
residues. Galactan and arabinan are bonded from C-5 of the β-
(1→6) link.
3-6
 Both galactosyl and arabinosyl units in mAG are 
in a furanose form, less stable thermodynamically than the 
pyranose form.
7
 It is believed that this plays a large role in raising 
the flexibility of the polysaccharide and making the mycolic 
acids (MAs) pack strongly by van de Waals interaction. Thereby, 
the structure of the cell wall has extremely low permeability and 
this provides the organism with high protection from drugs and 
from its environment.
1
 Therefore, studying and understanding 
mAG biosynthesis is an important strategy for developing new 
anti-TB drugs. Indeed, isoniazid and ethambutol, two of the 
standard antibiotics, target mAG biosynthesis; ethambutol 
inhibits arabinosyltransferases which contribute to the 
biosynthesis of the arabinan part of the polysaccharides while 
isoniazid inhibits mycolic acid biosynthesis.
8
 
It is approaching a century since Anderson began his ground 
breaking studies of the lipid components of mycobacteria, 
leading eventually to the characterization of MAs. These were 
shown to be high-molecular weight hydroxy acids, with an 
experimental formula of C88H172O4 or C88H176O4 which were very 
hard to purify and not possible to crystallize.
9,10 
The long alkyl 
branch on the α-position and hydroxyl groups in β-position in 
MAs was proved by Asselineau in 1950.
11
 Now over 500 related 
chemical structures of MAs isolated from Mycobacterium 
tuberculosis have been recognized.
12
 In brief, MAs can defined 
as a complex group of long chain fatty α-alkyl β-alkyl hydroxyl 
fatty acids (Figure 1).
13
 
 
Figure 1: Generalised mycolic acid structure 
The proximal group Y is generally a cis- alkene or cyclopropane, 
or a trans-alkene or cyclopropane with a further methyl 
substituent on the adjacent carbon distal from the hydroxyl acid. 
The distal group X is normally a cis-cyclopropane (α-MAs), a –
(CHMeCHOMe)- (methoxy MAs)  or a –(CHMeCO)- fragment 
(keto MAs).  Mixtures extracted from mycobacteria comprise 
many individual MA containing a range of functional groups X 
and Y (Figure 1) and but each also of several chain lengths.
14
 
Anderson & Geiger in 1937 claimed the first extraction of 
arabino-mycolate from the cell wall of Mycobacterium bovis 
using natural organic solvent.
15
 Some fifty years ago, the 
isolation of arabinose 5-mycolate by extraction of the cell walls 
of various mycobacteria under acidic conditions was reported.
16-
22
 More recently, mass spectrometry and NMR have provided 
powerful tools for the analysis of such molecules.
23 
Azuma and 
Yamamura in 1962 isolated arabinomycolate as a D-arabinose-5-
mycolate and proved it was toxic to mice.
17 
Inflammatory 
reactions similar to that observed after inoculation of live BCG 
were induced in the lungs by TMM, TDM or GMM isolated from 
BCG. However, the toxic reactions caused by GroMM and 
arabinose mono-mycolate were characterized by an acute 
inflammatory process.
24
 
 
In 2005, the preparation of a tetramycolyl pentaarabinose using a 
complex natural mixture of MAs was described.
25
 However, only 
in 2010 were structural studies of the composition of the 
arabinose mycolates of the cell wall of M. bovis reported. A two-
layer acid hydrolysis gave a number of fractions. One of these 
was a penta-arabinose tetramycolate, one was an arabinose 
mono-mycolate, while the others were hexa-arabinose, hepta-
arabinose and octa-arabinose tetramycolates. The mycolic acid 
methyl esters released from each of these showed a mass 
spectrometric pattern almost identical to the methyl esters 
obtained by hydrolysis of the original cell wall. A comparison of 
the penta-arabinose tetramycolate and arabinose monomycolate 
with samples prepared by combining a mixture of natural MAs 
with arabinose was reported.
26
 Ishiwata et al reported the 
synthesis of a series of mono-, di- and tetra-arabinomycolates 
found in the terminal position of cell wall skeleton of bacillus 
Calmette Guerin from M. bovis, by using natural mycolic acid 
mixtures extracted from the cell wall. They proved the biological 
activity for synthesized compounds in a tumor necrosis factor 
alpha (TNF-α) secretion-inducing assay; all the compounds 
showed strong TNF-α inducing activity in vitro.
25 
The 
mechanism of the activity of arabino-mycolate is not clear.
22
 
Synthetic arabino-mycolates induce the production of TNF-α in 
murine macrophage cell lines at an intensity similar to BCG-
CWS. However the immunological activity of natural arabino-
mycolates isolated from BCG has not been investigated, probably 
due to the complexity of the molecule.  Arabino-mycolates 
obtained by acid hydrolysis from CWS (SMP-105) of M. bovis 
BCG Tokyo 172 strain consisted mainly of mono-arabinose 
mono-mycolate, pentaarabinose tetra-mycolate and hexa-
arabinose tetramycolate fractions. Arabino-mycolates 
significantly induced TNF-α production with an intensity 
comparable to that of CWS and enhanced delayed type 
ypersensitivity (DTH) reactions against inactivated tumor cells. 
Arabino-mycolates-induced TNF-α production was completely 
dependent on TLR2 and MyD88 pathways. Thus isolated natural 
arabino-mycolates possess potent adjuvant immunostimulatory 
activity.
27
   
Intra-tumor injections of extracts of Re mutant Salmonella 
typhimurium in combination with TDM or arabinose mycolate 
were highly effective in producing regression of tumors in guinea 
pigs. Similar extracts from M. bovis strain BCG and strain AN5 
in combination with TDM also possessed tumor-regressive 
activity. The activity was reduced when the arabinose mycolate 
was substituted for the TDM. An extract of Coxiella burnetii, in 
combination with either TDM or arabinose mycolate was also 
active. Intracutaneous administration of Re glycolipid or aqueous 
extracts from BCG in combination with trehalose or arabinose 
mycolates did not produce life-threatening, clinical signs of 
toxicity in young mice. If additional toxicity studies demonstrate 
that adverse side effects can be satisfactorily controlled, these 
water soluble extracts may prove beneficial in the treatment of 
spontaneous tumors of humans and other animals.
28.29 
The 
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 3 
adjuvant activity of cell wall skeletons (mycolic acid-arabino-
galactan-mucopeptide, CWS) prepared from the cells of 
mycobacteria, nocardia and corynebacteria was examined in vivo 
in mice and guinea pigs. The cell wall skeletons of M. bovis BCG 
(BCG-CWS), Nocardia asteroides 131 and Corynebacterium 
diphtheriae PWC suspended in Freund's incomplete adjuvant 
(FIA) as water-in-oil emulsions showed potent adjuvant activity 
on the formation of circulating antibody and cell-mediated 
immunity to bovine serum albumin (BSA), sheep erythrocytes 
(SRBC) and sulfanylazo-bovine serum albumin (SA-BSA) in 
mice and guinea pigs. After acetylation or acid treatment, BCG-
CWS retained its adjuvant activity, but the activity of BCG-CWS 
was destroyed completely by alkaline treatment. The cell wall 
constituents, arabinose-mycolate and arabino-galactan, prepared 
from BCG-CWS showed no adjuvant activity.
30
 
Few studies
 
of arabinose mycolates have been carried out and 
little is known of the effect of structure on the 
immunostimulatury activity of arabino-mycolates in activating 
macrophages.
6
 However, D-arabinose-5-mycolate, purified from 
bound lipids of the cell-wall skeleton of M. bovis BCG may be 
prominent structure for recognition by host immunity.
6
  
 
 However, it is now clearly established that, in the case of free 
MAs, the detailed structure controls their effects on a range of 
cytokines and chemokines and that some lead to inflammatory 
reactions on intratracheal instillation in mice, while others lead to 
the formation of foam cells.
31
 we now report the synthesis of a set 
of arabinose esters of stereochemically defined synthetic MAs, as 
well as those of some simple fatty acids.  
 
2a Results and discussion: synthesis of arabinose mycolates 
According to literature procedures, D-(-)-arabinose 1 was treated 
with HCl (0.22 N) freshly prepared by addition of acetyl chloride 
to anhydrous methanol at 0 
0
C working up with pyridine rather 
than ammonium carbonate,
32 
to give methyl-α,β-D-arabino 
furanoside with predominant formation of the α-anomer (α-D/β-D 
3:2).
33,34
 In order to isolate these two anomers, in situ  tritylation 
of this mixture followed by column chromatography  gave 
methyl 5-O-trityl α-D-Araf 2 (45%) and 5-O-trityl β-D-Araf 3 
(30%). Compound 2 was benzylated to protect the two secondary 
hydroxyl groups by using benzyl bromide and sodium hydride in 
dry DMF then the trityl group was removed from the primary 
hydroxyl group by hydrolysis in 80% AcOH, affording 
compound 4 (Scheme 1).
25,34
   
 
 
Scheme 1. Reagents and conditions: (i) HCl, CH3OH; (ii) Trityl chloride, 
DMAP, pyridine, 0 ºC/R.T., then 70 ºC 4 h, 45% from α-anomer; (iii) a: 
NaH, BnBr, DMF, 0 ºC/R.T. 2 h, b: 80% AcOH, 75 ºC for 4 h, 78%; (iv) 4-
toluenesulfonyl chloride, DMAP, pyridine, 90%. 
 
 
According to the literature,
25
 direct esterification between 
the primary hydroxyl group of Araf and a carboxyl group in 
natural mycolic acid mixtures was achieved in a low yield (30%), 
while activating the sugar as a tosylate raised the yield to 79%. 
Therefore, the hydroxyl group in the compound 4 was tosylated 
by reaction with p-toluenesulfonyl chloride in dry pyridine and 
catalytic 4-dimethylaminopyridine (DMAP) in dry CH2Cl2 at 0 
ºC to afford the tosylate 5. Surprisingly, esters of arabinose with 
simple fatty acids do not appear to have been reported. In a 
model experiment, compound 4 was therefore first condensed 
with behenic acid using DMAP and N,N-dicyclohexylcarbodi-
imide in dry CH2Cl2 to give compound 7a  in 80% yield.
36
 This 
was then hydrogenolysed in the presence of Pd(OH)2 and under a 
hydrogen atmosphere to give the behenyl arabinose 8a. 
Compound 5 was also reacted with palmitic acid by an alkylative 
esterification using cesium hydrogen carbonate in dry DMF: THF 
at 70 
0
C,
25
 to give compound 7b; this was then debenzylated to 
give the compound 8b. In the same way, compound 5 was 
reacted with oleic acid to give the compound 7c; hydrogenolysis 
in the presence of Pd(OH)2 under a hydrogen atmosphere gave 
the corresponding stearyl arabinose, in which the double bond 
was also saturated. However, deprotection with boron trichloride 
in dichloromethane and methanol gave the oleoyl derivative 8c. 
A series of synthetic MAs was then reacted with the compound 5 
by alkylative esterification using cesium hydrogen carbonate as 
in Scheme 2. Firstly, the methoxy cis-cyclopropane mycolic acid 
6d,
37
 gave compound 7d, which was then debenzylated using 
hydrogen  and Pd(OH)2 catalyst to give the arabinose ester 8d. 
This was achieved with no loss of the cyclopropane group, on the 
basis of the proton and carbon NMR spectra. Although the 
absolute stereochemistry of the cis-cyclopropane unit in MAs 
remains unproven, this compound contains the stereochemistry 
that appears likely, based on a common intermediate leading to 
the different classes of mycolic acid.
38
 The 22 carbon length of 
the α-chain is typical of mycobacteria such as Mycobacterium 
kansasii.
39
 Condensation of methoxy-cis-cyclopropane mycolic 
acid 6e,
37
 having a twenty two carbon chain in the α-position, and 
the opposite absolute cis-cyclopropane stereochemistry, one 
stereoisomer of which is present in M. kansasii, led to compound 
7e. On hydrogenolysis as above, this gave compound 8e. In the 
same way, esterification of methoxy-cis-cyclopropane mycolic 
acid 6f,
40
 with a twenty four carbon chain at the α-position, a 
stereoisomer of which is a major component of M. tuberculosis 
methoxy-MA,
39
  but the opposite cyclopropane stereochemistry 
to 6d gave compound 7f, which on hydrogenolysis led to 
compound 8f.  
The same procedure was repeated to prepare the arabino ester 
compounds for the keto cis-cyclopropane mycolic acid 6g,
37
 with 
a C22 alkyl chain in the α-position; this was used as the epimeric 
mixture at the carbon adjacent to the ketone.  This produced 
compound 7g which on debenzylation gave the arabinose ester 
8g. Ester 8g’, with the normal C24 M. tuberculosis α-chain length, 
was also obtained from 6g’.
41
 In the same way the arabinose ester 
8h, from the keto trans-cyclopropane mycolic acid 6h,
42
 again 
epimeric adjacent to the ketone,  was obtained in good yield. 
Finally, the α-mycolic acid 6i,
43,44  
was esterified
  
to give 
compound 7i and then debenzylation to give 8i.  
The yields for each of these coupling steps and deprotections are 
given in Table 1. All the products were characterized by accurate 
mass MALDI-MS, proton and carbon NMR and the spectra are 
presented as Supplementary Information. 
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R =   stearate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
R 7 (%) 8 (%) 
a 80 81 
b 76 88 
c 83 64 
d 77 79 
e 75 65 
f 80 76 
g 80 63 
g’ 71 66 
h 92 80 
i 87 80 
Table 1: Yields for arabinose esters 
 
2b. Assessment of arabinose mycolates as antigens 
It is known that both trehalose esters of natural MAs, and the free 
acids themselves are antigenic to antibodies in the serum of 
patients infected with tuberculosis.
45,46 
As an initial study of the 
biological properties of the unique arabinose mycolates prepared 
in this work, their antigenicity to 64 serum samples taken from a 
Columbian population was determined using standard  enzyme-
linked immunosorbent assay (ELISA). The samples were all 
from individuals with symptoms of suspected tuberculosis. Nine 
were diagnosed as positive using a range of clinical and 
biochemical assays, culminating in culture, 39 as TB negative; 
the categorization was carried out by the World Health 
Organisation using standard protocols. The assay used IgG(Fc) 
conjugated secondary antibody to detect the disease antibody – 
antigen interaction. The full results of this study are provided as 
supplementary information, but are summarized in Table 2. This 
shows the average response and standard deviation for TB 
positive and negative samples, the cut-off response used in the 
assay, and the resulting sensitivity (% of TB+ diagnosed samples 
above the assay cut-off) and specificity (% of TB- samples 
correctly identified by the assay). 
 
 
7d 7e 7f 7g 7h 7i 
Average 
TB+ 0.64 0.40 0.78 0.50 0.48 1.18 
S/d 0.27 0.22 0.25 0.34 0.23 0.42 
Average 
TB- 0.39 0.33 0.46 0.44 0.45 0.52 
S/D 0.50 0.32 0.30 0.23 0.53 0.23 
 
 
     Cut-off >.35 >.27 >.45 >1.00 >.25 >.7 
True + 9 9 9 1 9 9 
False + 18 29 20 2 45 11 
 
 
     Sensitivity 100 100 100 11 100 100 
Specificity 67 47 64 96 18 80 
 
Table 2. Responses for a set of serum samples to arabinose 
mycolates coated as antigens on ELISA plates, using IgG(Fc) 
secondary antibody conjugate to determine the binding 
 
  R=  CH3(CH2)20  a,  CH3(CH2)14  b  R =   c               
 
 
R=       d 
 
R=       e      
 
R=   f      
R=    g n = 21 
       g’ n= 23    
R=       h      
R=     i      
 
Scheme 2: Synthesis of arabinose esters 
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This shows that the six synthetic arabinose mycolates are 
detected to a  different degree by antibodies in the serum of 
patients infected with active tuberculosis, and that in some cases 
the response is no different between TB+ and TB- samples. The 
TB status had been  determined using a range of standard assays 
employed by the WHO, including being smear and culture 
positive; the TB- samples were all from patients showing some of 
the symptoms of TB, but diagnosed using the same methods as 
not having active TB, and being both smear and culture negative. 
Although this is a very small sample set, it is interesting that the 
highest distinction between TB+/TB- is given with the arabinose 
mycolates 7d and 7i which probably represent the natural 
stereochemistires of methoxy- and alpha-mycolates. Work is on-
going to validate these results on a larger sample set. 
The effects of selected examples of the above synthetic arabinose 
mono-mycolates on the Mincle receptor in M. tuberculosis will 
be described elsewhere.
47
 
3. Experimental section 
Chemicals used were obtained from commercial suppliers 
(Sigma, Aldrich, and Alfa Aeser) or prepared from them by the 
methods described. Solvents which were required to be dry, e.g. 
ether, tetrahydrofuran were dried over sodium wire and 
benzophenone under nitrogen, while dichloromethane and 
HMPA were dried over calcium hydride. All reagents and 
solvents used were of reagent grade unless otherwise stated. 
Organic solutions were dried over anhydrous magnesium sulfate. 
Silica gel (Merck 7736) and silica gel plates used for column 
chromatography and thin layer chromatography were obtained 
from Aldrich; separated components were detected using 
variously UV light, I2 and phosphomolybdic acid solution in IMS 
followed by charring.   Infra-red (IR) spectra were carried out on 
a Perkin-Elmer 1600 F.T.I.R. spectrometer as liquid films or KBr 
disc (solid). Melting points were measured using a Gallenkamp 
melting point apparatus. NMR spectra were carried out on a 
Bruker AC250 or Advance 400 spectrometer. [α]D values were 
recorded in CHCl3 on a POLAAR 2001 optical activity 
polarimeter. Mass spectra were recorded on a Bruker matrix-
assisted laser desorption/ ionisation-time of flight mass 
spectrometry (MALDI-TOF MS) values are given plus sodium. 
3.1: Methyl 5-O-trityl-α-D-Araf 2 
Freshly prepared HCl solution in MeOH (resulting from mixing 
acetyl chloride (2 mL) in MeOH (30 mL) at 0 ºC) was added to a 
stirred solution of D-(-)-arabinose (5.0 g, 33 mmol) in anhydrous 
MeOH (100 mL). Stirring was continued overnight at room 
temperature, when a clear solution was obtained. The mixture 
was neutralized by adding pyridine to pH 7 – 8, and the solid was 
filtered and washed with MeOH (10 mL). The solvent was 
evaporated to give a residue which was purified by column 
chromatography eluting with chloroform: acetone (3:5) to give a 
colourless oil, methyl–α,β-D-Araf (4.3 g, 78%). Trityl chloride 
(6.42 g, 23.0 mmol) and 4-(dimethylamino)pyridine (2.57 g, 21.0 
mmol) were added to a stirred solution of methyl-α,β-D-Araf  
(3.12 g, 19.0 mmol) in anhydrous pyridine (60 mL) and the 
mixture was stirred at room temperature overnight then heated on 
oil bath at 70 ºC for 4 h. The mixture was cooled to room 
temperature and poured into ice/water (300 mL). The organic 
phase was separated and the aqueous phase was extracted with 
ethyl acetate (3 × 100 mL). The combined organic layers were 
washed with aq. NaHCO3 solution (5%, 100 mL), dried and the 
solvent was evaporated. The residue was purified by column 
chromatography eluting started from 10% to 50% hexane/ethyl 
acetate gave the title compound as a colorless oil 2 (3.3 g, 45%) 
and 5–O-trityl-β-D-Araf 3 (2.3 g, 30%). The mixture of anomers 
showed δH (400 MHz, CDCl3), δC (125 MHz, CDCl3) and vmax 
identical to the literature.
33.34 
 
 
3.2: Methyl 2,3-di-O-benzyl-α-D-Araf 4 
A solution of 2 (3.20 g, 7.88 mmol) in dry DMF (80 mL) was 
added dropwise to a stirred suspension of NaH (0.85 g) (60% 
w/w, dispersion in mineral oil, washed with petrol three times) at 
room temperature under nitrogen. The mixture was stirred for 30 
min. then benzyl bromide (2.5 mL, 3.6 g, 21.0 mmol) in dry 
DMF (50 mL) was added. The mixture was stirred at room 
temperature for 20 h and then quenched by slow addition of 
water (15 mL) and diluted with ether (25 mL). The organic layer 
was separated and the aqueous layer was extracted with ether (2 
× 100 mL). The combined extracts were washed with water (50 
mL), brine (50 mL), dried and evaporated under reduced 
pressure. Aqueous acetic acid (80%, 30 mL) was added to the 
crude product and the mixture was stirred and heated at 75 ºC for 
4 h, then diluted with water (20 mL) and ether (20 mL) and the 
organic layer was separated and the aqueous layer extracted with 
ether (2 × 100 mL). The combined organic layers were washed 
with water (50 mL), sat. aq. NaHCO3 (50 mL) and brine (50 mL), 
dried and the solvent was evaporated. Column chromatography 
eluting with petrol/ethyl acetate (7:3) gave the title compound as 
a colorless oil 4 (2.12 g, 78%) [MALDI-Found (M+Na)
+
: 367.3; 
C20H24NaO5, requires: 367.1], [] 22D +89 (c 0.10, CHCl3) [lit.
26
 
[]
24
D +83.2 (c 1.14, CHCl3)], which showed δH (400 MHz, 
CDCl3): 7.40 – 7.28 (10H, m), 4.95 (1H, s), 4.61 (1H, d, J 12.0 
Hz), 4.54 (1H, d, J 12 Hz), 4.53 (1H, d, J 12 Hz), 4.50 (1H, d, J 
12 Hz), 4.18 – 4.12 (1H, m), 4.02 – 3.96 (2H, m), 3.85 (1H, dd, J 
12.1, 2.8 Hz), 3.65 (1H, dd, J 12.1, 4.1 Hz), 3.40 (3H, s), 2.93 
(1H, br. s); δC (101 MHz, CDCl3): 137.6, 137.2, 128.4, 128.4, 
127.9, 127.8, 127.79, 127.7, 107.3, 87.6, 82.5, 82.2, 72.3, 71.8, 
62.1, 54.8;  νmax: 3466 br., 3089, 3064, 3031, 2925, 1725, 1605, 
1454, 739 cm
-1
. All data were identical to the literature.
25,34
  
 
3.3: Methyl 2,3-di-O-benzyl-5-O-p-toluensulfonyl-α-D-Araf 5 
p-Toluenesulfonyl chloride (0.60 g, 3.14 mmol) was added to a 
stirred solution of 4 (0.50 g, 1.45 mmol), pyridine (0.96 g, 
0.98mL,  12.4 mmol) and DMAP (0.10g, 0.81 mmol) in dry 
CH2Cl2 (5 mL) at 0 ºC. The mixture was stirred at room 
temperature for 16 h then diluted with ethyl acetate (10 mL), the 
organic layer was separated and the aqueous layer was re-
extracted with ethyl acetate (2 × 100 mL). The combined organic 
layer were washed with water (50 mL), brine (50 mL), dried and 
the solvent was evaporated. The residue was purified by column 
chromatography eluting with hexane/ethyl acetate (4:1) affording 
the title compound as a colorless oil 5 (0.65 g, 90%), [] 23
D
+55 
(c 0.10, CHCl3) [lit.
25
 [] 27
D
+57.0 (c 0.40, CHCl3)], which 
showed δH (400 MHz, CDCl3): 7.77 (2H, d, J 8.2 Hz), 7.41 – 
7.25 (12H, m), 4.85 (1H, s), 4.56 – 4.38 (4H, m), 4.22 – 4.15 
(1H, m), 4.12 (2H, br d, J 4.6 Hz), 3.94 (1H, br d, J 2.6 Hz), 3.81 
(1H, dd, J 5.9, 2.7 Hz), 3.33 (3H, s), 2.42 (3H, s); δC (101 MHz, 
CDCl3): 144.8, 137.3, 137.2, 132.7, 129.7, 128.4, 128.0, 127.9, 
127.89, 127.8, 127.79, 107.4, 87.5, 82.8, 79.2, 72.2, 71.9, 68.8, 
55.1, 21.6; νmax: 3064, 3032, 2916, 1741, 1454, 1365, 1177, 698 
cm
-1
. All data were identical to the literature.
25
  
 
3.4: Methyl 5-O-behenoyl-α-D-Araf 8a 
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Tetrahedron 6 
(a) A solution of N,N`-dicyclohexylcarbodimide (0.089 g, 
0.432 mmol) in dry CH2Cl2 (1 mL) was added dropwise to a 
stirred solution of 4 (0.10g, 0.29 mmol), DMAP  (0.042 g, 0.343 
mmol) and behenic acid (0.10 g, 0.29 mmol) in dry CH2Cl2 (1 
mL) at 0 ºC under nitrogen. The mixture was stirred for 30 min. 
then  the precipitate of dicyclohexyl urea was filtered off and 
washed with CH2Cl2 (10 mL), the solvent was evaporated and 
the residue was purified by column chromatography eluting 
with hexane/ethyl acetate (10:1) to afford methyl 2,3-di-O-
benzyl-5-O-behenoyl-α-D-Araf
31
 as a colorless oil  7a (0.15 g, 
80%) [MALDI-Found (M+Na)+: 689.5, C42H66NaO6 requires: 
689.4], [] 24
D
+40 (c 0.10, CHCl3), which showed  δH (500 
MHz, CDCl3): 7.41 – 7.28 (10H, m), 4.95 (1H, s), 4.59 (1H, d, J 
12.0 Hz), 4.57 (1H, d, J 12 Hz), 4.52 (1H, d, J 12 Hz), 4.49 (1H, 
d, J 12 Hz), 4.29 (1H, dd, J 11.3, 2.8 Hz), 4.24 – 4.15 (2H, m), 
4.01 (1H, dd, J 2.9, 1.1 Hz), 3.84 (1H, dd, J 6.3, 2.9 Hz), 3.40 
(3H, s), 2.33 – 2.26 (2H, m), 1.64 – 1.52 (2H, m), 1.34 – 1.18 
(36H, m), 0.89 (3H, t, J 6.9 Hz); δC (101 MHz, CDCl3): 173.6, 
137.5, 137.4, 128.45, 128.43, 127.9, 127.8, 107.3, 88.0, 83.4, 
79.4, 72.3, 72.0, 63.5, 55.0, 34.1, 31.9, 29.7, 29.6, 29.62, 29.5, 
29.3, 29.27, 29.1, 24.8, 22.7, 14.1;  νmax: 3034, 2915, 2849, 
1741, 1471, 1100, 758 cm
-1
. 
(b) Palladium hydroxide on activated charcoal (20% Pd(OH)2-C, 
0.0026 g, 0.15 fold by weight) was added to a stirred solution of 
7a (0.010g, 0.01 mmol) in dry CH2Cl2: MeOH (1:1, 2 mL) at 
room temperature  under hydrogen atmosphere. The reaction 
mixture was stirred for 24 h then filtered and the precipitate 
washed with CH2Cl2 (10 mL), the filtrate was evaporated and the 
residue was purified by column chromatography eluting with 
hexane/ethyl acetate (1:1) to afford the title compound as a 
colorless oil 8a (0.0079 g, 81%) [MALDI-Found  (M+Na)
+
: 
509.5, C28H54NaO6 requires: 509.3],  [] 22D +46 (c 0.10, CHCl3), 
which showed δH (500 MHz, CDCl3): 4.92 (1H, s), 4.32 – 4.29 
(2H, m), 4.22 (1H, dd, J 7.1, 3.9 Hz), 4.09 (1H, br. s), 3.90 (1H, 
br.s), 3.42 (3H, s), 2.81 – 2.67 (1H, m), 2.51 – 2.39 (1H, m), 2.38 
– 2.32 (2H, m), 1.62 (2H, dd, J 14.7, 7.3 Hz), 1.35 – 1.20 (36H, 
m), 0.89 (3H, t, J 7.0 Hz); δC (101 MHz, CDCl3): 173.5, 108.8, 
83.7, 79.8, 78.0, 63.8, 55.0, 34.1, 31.9, 29.7, 29.6, 29.5, 29.4, 
29.3, 29.2, 29.0, 24.8, 22.6, 14.1 ; νmax: br. 3500, 2917, 
2850,1739, 1464, 1100,758 cm
-1
. 
 
3.5: Methyl 2,3-di-O-benzyl-5-O-palmitoyl-α-D-Araf 8b  
(a) Cesium hydrogen carbonate  (0.19 g, 1.0 mmol) was added to 
a stirred solution of 5 (0.1 g, 0.2 mmol) and palmitic acid (0.061 
g, 0.237 mmol) in dry DMF:THF (1: 5, 5 mL) at room 
temperature and the reaction mixture was stirred at 70 ºC for two 
days. The suspension was diluted with ethyl acetate (10 mL) and 
water (10 mL). The organic layer was separated and the aqueous 
layer was re-extracted with ethyl acetate (2 × 10 mL). The 
combined organic layers were washed with water (15 mL) and 
brine (15 mL), dried, filtered and evaporated to give a thick oil 
residue. The residue was purified by column chromatography 
eluting with hexane/ethyl acetate (10:1) to give methyl 2,3-di-O-
benzyl-5-O-palmitoyl-α-D-Araf 7b (0.089 g, 76%).
25
 as a 
colorless oil [MALDI-Found  (M+Na)+ : 605.1, C36H54NaO6 
requires: 605.3], [] 22
D
+37 (c 0.10, CHCl3), which showed δH 
(500 MHz, CDCl3): 7.39 – 7.28 (10H, m), 4.95 (1H, s), 4.59 (1H, 
d, J 12.0 Hz), 4.57 (1H, d, J 11.7 Hz), 4.52 (1H, d, J 12.0 Hz), 
4.49 (1H, d, J 11.8 Hz), 4.29 (1H, dd, J 11.3, 2.9 Hz), 4.24 – 4.15 
(2H, m), 4.01 (1H, dd, J 3.0, 1.2 Hz), 3.84 (1H, dd, J 6.2, 2.9 
Hz), 3.40 (3H, s), 2.32 – 2.27 (2H, m), 1.64 – 1.54 (2H, m), 1.26 
(24H, s), 0.89 (3H, t, J 7.0 Hz);  δC (101 MHz, CDCl3): 173.6, 
137.5, 137.3, 128.4, 128.3, 127.9, 127.8, 107.3, 88.0, 83.4, 79.3, 
72.3, 72.0, 63.5, 54.9, 34.1, 31.9, 29.7, 29.68, 29.6, 29.4, 29.32, 
29.3, 29.1, 24.8, 22.7, 14.1; νmax: 3064, 3032, 2924, 2853, 1740, 
1455, 1365, 1107, 735 cm
-1
 .  
(b) Palladium hydroxide on activated charcoal (20% Pd(OH)2-C , 
0.01 g, 0.15 fold by weight ) was added  to a stirred solution of 
7b (0.06 g, 0.10 mmol) in dry CH2Cl2 : MeOH, (1:1, 2 mL) at 
room temperature  under hydrogen atmosphere. The reaction 
mixture was stirred for 24 h then filtered and the precipitate was 
washed with CH2Cl2 (10 mL), the filtrate was evaporated and the 
residue was purified by column chromatography eluting with 
hexane/ethyl acetate (1:1) to afford the title compound as a 
colorless oil 8b (0.04 g, 88%),
34
 [] 18
D
+1.2 (c 0.10, CHCl3) 
[MALDI-Found  (M+Na)
+
: 425.5, C22H42NaO6 requires: 425.2] 
which showed δH (500 MHz, CDCl3): 4.93 (1H, s), 4.33 – 4.30 
(2H, m), 4.22 (1H, dd, J 6.9, 3.9 Hz), 4.09 (1H, br. s), 3.91 (1H, 
br. s), 3.43 (3H, s), 2.35 (2H, t, J 7.6 Hz), 1.67 – 1.60 (2H, m), 
1.56 (2H, br. s), 1.36 – 1.21 (24H, m), 0.89 (3H, t, J 6.9 Hz); δC 
(101 MHz, CDCl3): 173.5, 108.8, 83.8, 79.8, 78.0, 63.8, 55.1, 
34.1, 31.9, 29.6, 29.6, 29.5, 29.4, 29.3, 29.2, 29.0, 24.8, 22.6, 
14.1 ; νmax: br. 3308, 2916, 2848, 1742, 1472, 1099, 728 cm
-1
. 
 
3.6: Methyl 5-O-oleoyl-α-D-Araf 8c 
(a) Cesium hydrogen carbonate (0.47 g, 2.42 mmol) was added to 
a stirred solution of 5 (0.26 g, 0.52 mmol) and oleic acid (0.10 g, 
0.35 mmol) in dry DMF:THF (1:5, 2 mL) at room temperature 
and the mixture was stirred at 70 ºC for two days. The suspension 
was diluted with ethyl acetate (10 mL) and water (10 mL). The 
organic layer was separated and the aqueous layer was re-
extracted with ethyl acetate (2 × 10 mL). The combined organic 
layers were washed with water (15 mL) and brine (15 mL). The 
organic layer was dried, filtered and evaporated to give a thick oil 
residue. This was purified by column chromatography eluting 
with hexane/ethyl acetate (7:2) to afford methyl 2,3-di-O-benzyl-
5-O-oleoyl-α-D-Araf as a colorless oil 7c (0.18 g, 83%) 
[MALDI-Found  (M+Na)
+
 : 631.3, C38H56NaO6 requires : 631.4], 
[] 22
D
+45  (c 0.10, CHCl3) which showed δH (400 MHz, CDCl3):  
7.39 – 7.28 (10H, m), 5.41 – 5.30 (2H, m), 4.95 (1H, s), 4.59 
(1H, d, J 12.0 Hz), 4.57 (1H, d, J 12 Hz), 4.52 (1H, d, J 12 Hz), 
4.49 (1H, d, J 12 Hz), 4.29 (1H, dd, J 11.0, 2.5 Hz), 4.24 – 4.15 
(2H, m), 4.0 (1H, br d, J 2.1 Hz), 3.84 (1H, dd, J 6.2, 2.8 Hz), 
3.40 (3H, s), 2.30 (2H, t, J 7.6 Hz), 2.06 – 1.97 (4H, m), 1.64 – 
1.54 (4H, m), 1.28 (18H, br m), 0.89 (3H, t, J 6.8 Hz); δC (101 
MHz, CDCl3): 173.6, 137.5, 137.4, 130.0, 129.7, 128.5, 128.4, 
127.9, 107.3, 87.9, 83.3, 79.3, 72.3, 72.0, 63.5, 55.0, 34.0, 31.9, 
29.7, 29.6, 29.5, 29.3, 29.17, 29.11, 29.1, 27.25, 27.2, 24.8, 22.6, 
14.1; νmax: 3005, 3089, 3031, 2926, 2855, 1740, 1454, 1050, 735 
cm
-1
. 
(b) Boron trichloride
48
 (0.32 mL, 1M) was added to a stirred 
solution of compound (7c) (0.02 g, 0.03 mmol) in dry CH2Cl2 (2 
mL) at -78 ºC. The mixture was stirred for 2 h then quenched 
with CH2Cl2:MeOH (1:1, 2 mL) and the solvent was evaporated 
and the residue was purified by column chromatography eluting 
with hexane/ethyl acetate (1:1) to afford the title compound (7c) 
(9 mg, 64%) [Found (MALDI) (M+Na)
+
: 451.3, C24H44NaO6 
requires: 451.3], []18
D
 +5.0 (c 0.10, CHCl3) which showed δH 
(400 MHz, CDCl3 + few drops CD3OD): 5.35 – 5.26 (2H, m), 
4.77 (1H, d, J 4.3 Hz), 4.24 (1H, dd, J 11.7, 2.1 Hz), 4.11 – 4.05 
(1H, m), 4.02 – 3.97 (1H, m), 3.97 – 3.91 (2H, m), 3.39 (3H, s), 
2.32 (2H, t, J 7.6 Hz), 2.04 – 1.92 (4H, m), 1.65 – 1.54 (2H, m), 
1.35 – 1.15 (22H, m), 0.84 (3H, t, J 6.7 Hz); δC (101 MHz, 
CDCl3 + few drops CD3OD): 174.3, 129.96, 129.7, 102.3, 79.9, 
77.7, 75.8, 65.4, 55.2, 49.6, 49.3, 49.1, 48.9, 48.7, 34.1, 31.8, 
29.7, 29.6, 29.4, 29.2, 29.1, 29.0, 27.1, 27.09, 24.8, 22.6, 13.98; 
νmax: br. 3468, 2917, 2850, 1735, 1454, 1050, 824 cm
-1
. 
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 7 
3.7: Methyl 5-O-stearyl-α-D-Araf  
Palladium hydroxide on activated charcoal (20% Pd(OH)2-C, 
0.012 g, 0.15 fold by weight) was added to a  stirred solution of 
7c (0.08 g, 0.13 mmol) in dry (CH2Cl2 : MeOH, 1:1, 3 mL) at 
room temperature under hydrogen atmosphere. The mixture was 
stirred for 24 h then filtered and the precipitate washed with 
CH2Cl2 (15 mL), the filtrate was evaporated and the residue was 
purified by column chromatography eluting with hexane / ethyl 
acetate (1:1) to afford the title compound as a colorless oil  
(0.045 g, 80%) [MALDI-Found (M+Na)
+
: 453.0, C24H46NaO6 
requires: 453.3];  [] 18
D
+2 (c 0.1, CHCl3); δH (400 MHz, CDCl3): 
4.92 (1H, s), 4.30 (2H, d, J 4.0 Hz), 4.21 (1H, dd, J 7.3, 3.8 Hz), 
4.17 – 4.06 (1H, m), 3.90 (1H, br d, J 10.1 Hz), 3.42 (3H, s), 2.77 
(1H, d, J 10.2 Hz), 2.52 (1H, d, J 7.9 Hz), 2.35 (2H, t, J 7.6 Hz), 
1.69 – 1.58 (2H, m), 1.34 – 1.21 (28H, m), 0.88 (3H, t, J 6.8 Hz); 
δC (101 MHz, CDCl3): 173.5, 108.8, 83.7, 79.8, 78.0, 63.8, 55.1, 
50.8, 34.1, 31.9, 29.7, 29.6, 29.6, 29.4, 29.3, 29.2, 29.05, 24.79, 
22.67, 14.10; νmax: br. 3468, 2917, 2850, 1735, 1454, 1050, 824 
cm
-1
. 
 
3.8: Methyl 5-O-(2-{(R)-1-hydroxy-18-[(1S, 2R)-2-[(17S, 18S) 
-17-methoxy-18-methylhexatriacontyl]cyclopropyl]octadecyl} 
tetracosanoate) α-D-Araf 8d 
(a) Cesium hydrogen carbonate (0.056 g, 0.288 mmol) was added 
to a solution of 5 (0.031g, 0.062 mmol) and (R)-2-{(R)-1-
hydroxy-18-[(1S,2R)-2-((17S,18S)-17-methoxy-18-
methylhexatriacontyl) cyclopropyl]octadecyl}tetracosanoic acid 
(0.051g, 0.041 mmol)
37
 in dry DMF:THF (1:5, 2 mL) at room 
temperature and the mixture was stirred at 70 ºC for two days. 
Work up as before gave methyl 2,3-di-O-benzyl-5-O-(2-{(R)-1-
hydroxy-18-[(1S,2R)-2-[(17S,18S )-17-methoxy-18-
methylhexatriacontyl]cyclopropyl]octadecyl}- tetracosanoate) α-
D- Araf 7d as a thick colorless oil (0.05 g, 77%), [Found  
(M+Na)
+
:1574.4044, C103H186NaO8  requires: 1574.4040]; [] 20D
+23 (c 0.10, CHCl3); δH (400 MHz, CDCl3): 7.39 – 7.28 (10H, 
m), 4.92 (1H, s), 4.58 (1H, d, J 12.0 Hz), 4.56 (1H, d, J 12 Hz), 
4.51 (1H, d, J 12 Hz), 4.48 (1H, d, J 12 Hz), 4.33 – 4.27 (2H, m), 
4.25 – 4.19 (1H, m), 3.99 (1H, br d, J 2.0 Hz), 3.84 (1H, dd, J 
6.4, 2.6 Hz), 3.67 – 3.59 (1H, m), 3.37 (3H, s), 3.35 (3H, s), 2.99 
– 2.94 (1H, m), 2.52 (1H, d, J 8.3 Hz), 2.43 (1H, dt, J 9.4, 5.4 
Hz), 1.72 – 1.61 (2H, m), 1.59 – 1.03 (141H, m), 0.89 (6H, t, J 
6.8 Hz), 0.86 (3H, d, J 6.9 Hz), 0.70 – 0.61 (2H, m), 0.60 – 0.53 
(1H, dt, J 4, 8 Hz), –0.33 (1H, br. q J 5.1 Hz); δC (101 MHz, 
CDCl3): 175.0, 128.5, 128.4, 127.9, 127.8, 107.2, 87.9, 85.4, 
83.7, 79.4, 72.4, 72.1, 63.5, 57.7, 54.9, 51.53, 35.52, 35.3, 32.36, 
31.9, 30.5, 30.48, 30.4, 30.3, 30.23, 30.12, 30.0, 29.98, 29.94, 
29.9, 29.86, 29.84, 29.7, 29.6, 29.5, 29.4, 29.3, 29.3, 29.26, 29.2, 
29.19, 29.1, 29.0, 29.04, 28.7, 28.67, 27.5, 27.4, 26.1, 25.7, 22.7, 
22.6, 15.7, 14.8, 14.1, 10.9; νmax: 3479, 3064, 2924, 2853, 1735, 
1494, 1455, 1100 cm
-1
. 
(b) Palladium hydroxide on activated charcoal (20%  Pd(OH)2-C 
, 0.0033 g , 0.15 fold by weight) was added to a stirred solution 
of 7d (0.022 g, 0.014 mmol) in dry CH2Cl2 : MeOH (1:1, 2 mL) 
at room temperature under hydrogen atmosphere. The mixture 
was stirred overnight; work up as before gave the title compound 
as a thick colorless oil 8d (0.016 g, 79%) [Found (M+NH4)
+
:  
1389.3550,  C89H178NO8 requires: 1389.3552];  [] 21D +28 (c 
0.10, CHCl3); δH (400 MHz, CDCl3): 4.89 (1H, s), 4.49 (1H, dd, 
J 12, 4.0 Hz), 4.35 (1H, dd, J 12, 4.1 Hz), 4.21 – 4.15 (1H, m), 
4.07 (1H, br.s), 3.98 (1H, br.s), 3.77 – 3.66 (1H, m), 3.41 (3H, s), 
3.35 (3 H, s), 3.01 – 2.92 (1H, m), 2.85 (1H, s), 2.54 – 2.36 
(1H, ddd, J 10.1, 6.9, 5.1 Hz), 1.48 – 1.17 (144H, m), 0.89 (6H, t, 
J 6.8 Hz), 0.86 (3H, d, J 6.9 Hz), 0.70 – 0.61 (2H, m), 0.61 – 
0.52 (1H, dt, J 7.9, 3.9 Hz), -0.33 (1H, br. q J  5.1 Hz); δC (101 
MHz, CDCl3): 174.9, 108.7, 85.4, 83.6, 80.5, 78.4, 72.8, 63.2, 
57.7, 54.9, 52.3, 35.3, 35.2, 32.3, 31.9, 30.7, 30.69, 30.64, 30.62, 
30.55, 30.5, 30.4, 30.37, 30.3, 30.28, 30.2, 30.1, 30.0, 29.9, 29.8, 
29.7, 29.6, 29.57, 29.55, 29.5, 29.4, 29.3, 29.28, 29.25, 29.2, 
29.1, 29.0, 29.03, 29.0, 28.9, 28.7, 28.6, 28.5, 28.3, 27.5, 27.4, 
26.1, 25.4, 22.6, 15.7, 14.8, 14.1, 10.9; νmax: br.3435, 2918, 2850, 
1732, 1455,1100 cm
-1
. 
 
3.9: Methyl 5-O-(2-[(R)-1-hydroxy-18-[(1R ,2S)-2-[(17S,18S)-
17-methoxy-18-methylhexatriacontyl]cyclo propyl]octadecyl-
]tetracosanoate) α-D-Araf 8e 
(a) Cesium hydrogen carbonate  (0.098 g, 0.505 mmol) was 
added to a stirred solution of 5 (0.0546 g, 0.1000 mmol) and  (R)-
2-{(R)-1-hydroxy-18-[(1R,2S)-2-((17S,18S)-17-methoxy-18-
methyl-hexatriacontyl)cyclopropyl]octadecyl}tetracosanoic acid 
(0.100 g, 0.081 mmol)
37
 in dry DMF:THF (1:5, 2 mL) at room 
temperature and the reaction mixture was stirred at 70 ºC for two 
days. The suspension was diluted with ethyl acetate (10 mL) and 
water (10 mL). The organic layer was separated and the aqueous 
layer was re-extracted with ethyl acetate (2 × 10 mL). The 
combined organic layers were washed with water (15 mL) and 
brine (15 mL), then dried, filtered and evaporated to give a thick 
oil residue. The residue was purified by column chromatography 
eluting with hexane/ethyl acetate (10:1) to give methyl 2,3-di-O-
benzyl-5-O-(2-[(R)-1-hydroxy-18-[(1R,2S)-2-[(17S,18S)-17-
methoxy-18-methyl-hexatriacontyl]-
cyclopropyl]octadecyl]tetracosanoate)α-D-Araf as a colorless 
thick oil 7e (0.095 g, 75%) [Found (M+Na)
+
: 1574.4085, 
C103H186NaO8 requires: 1574.4040], [] 23D +18 (c 0.10, CHCl3), 
which showed δH (500 MHz, CDCl3): 7.38 – 7.29 (10H, m), 4.92 
(1H, s), 4.58 (1H, d, J 12 Hz), 4.56 (1H, d, J 12 Hz), 4.51 (1H, d, 
J 12 Hz), 4.48 (1H, d, J 12 Hz), 4.31 – 4.28 (2H, m), 4.24 – 4.20 
(1H, m), 3.99 (1H, dd, J 2.7, 0.9 Hz), 3.84 (1H, dd, J 6.4, 2.6 
Hz), 3.66 – 3.60 (1H, m), 3.38 (3H, s), 3.35 (3H, s), 3.00 – 2.93 
(1H, m), 2.52 (1H, br. s), 2.43 (1H, dt, J 9.1, 5.5 Hz), 1.72 – 1.61 
(2H, m), 1.60 – 1.07 (141H, m), 0.89 (6H, t, J 6.9 Hz), 0.86 (3H, 
d, J 6.8 Hz), 0.69 – 0.62 (2H, m), 0.57 (1H, dt, J 8.4, 4.1 Hz), – 
0.32 (1H, q, J 5.2 Hz); δC (101 MHz, CDCl3): 175.0, 137.5, 
137.3, 128.6, 128.5, 127.9, 127.8, 107.2, 87.9, 85.4, 83.7, 79.4, 
72.4, 72.2, 72.1, 63.5, 57.7, 54.9, 51.5, 35.5, 35.3, 32.5, 32.3, 
31.9, 31.3, 31.0, 30.9, 30.8, 30.79, 30.6, 30.58, 30.5, 30.47, 30.4, 
30.38, 30.37, 30.3, 30.29, 30.2, 30.19, 30.1, 29.9, 29.8, 29.7, 
29.6, 29.5, 29.4, 29.3, 29.2, 29.18, 29.17, 29.16, 29.15, 29.0, 
28.9, 28.8, 28.7, 28.5, 28.4, 28.3, 27.6, 27.4, 27.3, 26.9, 26.1, 
25.7, 22.6, 15.7, 14.8, 14.1, 10.9 ; νmax : 3479, 3064, 2923, 2853, 
1733, 1465, 1100, 721 cm
-1
. 
(b) Palladium hydroxide on activated charcoal (20% Pd(OH)2-C , 
0.003 g , 0.15 fold by weight) was added  to a stirred solution of 
7e (0.020 g, 0.012 mmol) in dry CH2Cl2 : MeOH (1:1, 2 mL) at 
room temperature under hydrogen atmosphere. The mixture was 
stirred overnight then filtered and the solvent was evaporated to 
give a residue; column chromatography eluting with hexane/ethyl 
acetate (1:1) gave the title compound as a colorless oil 8e (0.011 
g, 65%) [Found (M+Na)
+
: 1394.3138, C89H174NaO8 requires: 
1394.3101],  [] 16
D
 +10 (c 0.70, CHCl3);
 
δH (400 MHz, CDCl3): 
4.89 (1H, s), 4.50 (1H, dd, J 12, 3.8 Hz), 4.32 (1H, dd, J 12, 4.4 
Hz), 4.20 – 4.16 (1H, m), 4.07 (1H, d, J 5.6 Hz), 4.00 – 3.96 (1H, 
m), 3.74 – 3.64 (1H, m), 3.41 (3H, s), 3.35 (3H, s), 3.00 – 2.93 
(1H, m), 2.79 – 2.7 (2H, m), 2.48 – 2.39 (1H, m), 2.39 – 2.32 
(1H, m), 1.6 – 1.05 (143H, m), 0.89 (6H, t, J 6.8 Hz), 0.86 (3H, 
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d, J 6.9 Hz), 0.69 – 0.63 (2H, m), 0.60 – 0.53 (1H, dt J ), -0.32 
(1H, br. q J 4.5 Hz);
  
δC (101 MHz, CDCl3): 174.9, 108.7, 85.4, 
83.8, 80.4, 78.4, 72.8, 63.2, 57.7, 55.0, 52.2, 35.3, 35.2, 32.3, 
31.9, 30.5, 30.2, 30.0, 29.9, 29.7, 29.68, 29.6, 29.5, 29.4, 29.3, 
28.7, 27.5, 27.4, 26.1, 25.4, 22.7, 15.7, 14.99, 14.1, 10.9; νmax: br. 
3436, 2918, 2850, 1732, 1467, 1099, 720 cm
-1
.
  
 
3.10: Methyl 5-O-(2-[(R)-1-hydroxy-18-[(1R, 2S)-2-[(17S, 18 
S)-17-methoxy-18-methylhexatriacontyl]cyclopropyl]octa- 
decyl] hexacosanoate) α-D-Araf 8f 
 
(a) Cesium hydrogen carbonate  (0.083 g, 0.428 mmol) was 
added with stirring to 5 (0.0457 g, 0.091 mmol) and (R)-2-{(R)-
1-hydroxy-18-[(1R,2S)-2-((17S,18S)-17-methoxy-18-
methylhexa- triacontyl)cyclopropyl]octadecyl}hexacosanoic acid 
(0.076 g, 0.060 mmol)
40
 in dry DMF:THF (1:5, 2 mL) at room 
temperature and the mixture was stirred at 70 ºC for two days 
then worked up as before to give methyl 2,3-di-O-benzyl-5-O-(2-
[(R)-1-hydroxy-18-[(1R,2S)-2-[(17S,18S)-17-methoxy-18-
methylhexatriacontyl]- cyclopropyl]octadecyl]hexacosanoate)α-
D-Araf 7f (0.077 g, 80%) as a thick colorless oil [Found 
(M+Na)
+
: 1602.4304, C105H190NaO8 requires: 1602.4353], [] 22D
+18 (c 0.10, CHCl3), which showed δH (400 MHz, CDCl3): 7.39 
– 7.28 (10H, m), 4.92 (1H, s), 4.58 (1H, d, J 12 Hz), 4.56 (1H, d, 
J 12 Hz), 4.51 (1H, d, J 12 Hz), 4.48 (1H, d, J 12 Hz), 4.31 – 
4.28 (2H, m), 4.26 – 4.19 (1H, m), 4.0 (1H, dd, J 5.6, 2.5 Hz), 
3.84 (1H, dd, J 6.3, 2.5 Hz), 3.68 – 3.58 (1H, m), 3.37 (3H, s), 
3.35 (3H, s), 3.00 – 2.93 (1H, m), 2.50 (1H, d, J 8.2 Hz), 2.44 
(1H, dt, J 8.7, 5.4 Hz), 1.75 – 1.56 (2H, m), 1.58 – 1.04 (145H, 
m), 0.89 (6H, t, J 6.8 Hz), 0.86 (3H, d, J 6.9 Hz), 0.70 – 0.62 
(2H, m), 0.57 (1H, dt, J 8 4 Hz), -0.32 (1H, br. q  J 5.0 Hz); δC 
(101 MHz, CDCl3): 175.0, 137.4, 137.3, 128.5, 128.4, 128.0, 
127.9, 127.89, 127.88, 127.87, 127.86, 107.2, 87.8, 85.4, 83.7, 
79.4, 72.4, 72.2, 72.1, 63.4, 57.7, 54.9, 51.5, 35.5, 35.3, 32.4, 
31.9, 30.8, 30.7, 30.67, 30.6, 30.55, 30.5, 30.45, 30.4, 30.38, 
30.37, 30.36, 30.2, 30.17, 30.16, 30.15, 30.0, 29.9, 29.8, 29.7, 
29.6, 29.5, 29.4, 29.3, 29.27, 29.26, 29.2, 29.14, 29.1, 29.07, 
29.02, 29.01, 28.94, 28.9, 28.7, 28.65, 28.6, 28.52, 28.5, 27.5, 
27.4, 26.1, 25.7, 22.6, 15.7, 14.8, 14.1, 10.9 ; νmax: br. 3522, 
3064, 2921, 2851 , 1723, 1467, 1027, 732 cm
-1
. 
(b) Palladium hydroxide on activated charcoal (20% Pd(OH)2-C, 
0.003 g, 0.15 fold by weight) was added to a stirred solution of 7f 
(0.020 g, 0.012 mmol) in dry CH2Cl2 : MeOH (1:1, 2 mL) at 
room temperature under hydrogen atmosphere. The mixture was 
stirred overnight then worked up as before to give the title 
compound as a thick colorless oil 8f (0.014 g, 76%) [Found 
(M+Na)
+
:   1422.3425, C91H178NaO8 requires: 1422.3414]; [] 21D
+10 (c 0.10, CHCl3);
 
δH (400 MHz, CDCl3): 4.89 (1H, s), 4.51 
(1H, dd, J 12, 3.9 Hz), 4.33 (1H, dd, J 12.0, 4.1 Hz), 4.21 – 4.15 
(1H, m), 4.07 (1H, br. s), 4.01 – 3.95 (1H, m), 3.75 (1H, d, J 5.3 
Hz), 3.73 – 3.66 (1H, m), 3.41 (3H, s), 3.35 (3H, s), 3.00 – 2.93 
(1H, m), 2.85 – 2.70 (2H, m), 2.50 – 2.39 (1H, m), 1.72 – 1.61 
(2H, m), 1.60 – 1.03 (145H, m), 0.89 (6H, t, J 6.8 Hz), 0.85 (3H, 
d, J 6.8 Hz), 0.70 – 0.61 (2H, m), 0.60 – 0.53 (1H, dt, J 8, 4 Hz), 
-0.33 (1H, br. q, J  5.2 Hz);
  
δC (101 MHz, CDCl3): 175.0, 108.7, 
85.5, 83.8, 80.4, 78.4, 72.8, 63.2, 57.7, 55.0, 52.2, 35.3, 35.2, 
32.3, 31.9, 30.5, 30.2, 29.9, 29.89, 29.7, 29.6, 29.6, 29.5, 29.4, 
29.3, 28.7, 27.6, 27.4, 26.1, 22.4, 22.7, 15.77, 14.8, 14.1, 10.9; 
νmax: br. 3436, 2921, 2852, 1732, 1493, 1455, 759  cm
-1
. 
 
3.11: Methyl 5-O-(2-[(1R)-1-hydroxy-16-[(1R,2S)-2-[20-
methyl-19-oxooctatriacontyl]cyclopropyl] hexadecyl] tetra-
cosanoate) α-D-Araf  8g 
(a) Cesium hydrogen carbonate (0.086 g, 0.443 mmol) was added 
to a stirred solution of 5 (0.0475 g, 0.0953 mmol) and (R)-2-{(R)-
1-hydroxy-16-[(1R,2S)-2-((S)-20-methyl-19-oxo-octatriacontyl)-
cyclopropyl]-hexadecyl}-tetracosanoic acid (0.077 g, 0.063 
mmol)
41
 in dry DMF:THF (1:5, 2 mL) at room temperature and 
stirred at 70 ºC for two days. Work up as before gave methyl 2,3-
di-O-benzyl-5-O-(2-[(1R)-1-hydroxy-16-[(1R,2S)-2-[20-methyl-
19-oxooctatriacontyl]cyclopropyl]hexadecyl]tetracosanoate) α-
D-Araf as a thick colorless oil 7g (0.077 g, 80%) [Found 
(M+NH4)
+
: 1558.3708, C104H190NO8 requires: 1558.3727], [] 21D
+21 (c 0.10, CHCl3); δH (400 MHz, CDCl3): 7.39 – 7.28 (10H, 
m), 4.92 (1H, s), 4.58 (1H, d, J 12.0 Hz), 4.56 (1H, d, J 12 Hz), 
4.51 (1H, d, J 12 Hz), 4.48 (1H, d, J 12 Hz), 4.32 – 4.28 (2H, m), 
4.25 – 4.19 (1H, m), 3.99 (1H, br d, J 2.2 Hz), 3.84 (1H, dd, J 
6.4, 2.8 Hz), 3.67 – 3.59 (1H, m), 3.38 (3H, s), 2.57 – 2.47 (2H, 
m), 2.47 – 2.38 (3H, m), 1.75 – 1.09 (140H, m), 1.06 (3H, d, J 
6.9 Hz), 0.89 (6H, t, J 6.7 Hz), 0.70 – 0.62 (2H, m), 0.61 – 0.53 
(1H, dt, J 3.9, 7.9 Hz), -0.32 (1H, br. q, J  5.2 Hz); δC (101 MHz, 
CDCl3): 215.2, 175.0, 137.5, 137.3, 128.5, 128.4, 127.9, 127.9, 
127.8, 107.2, 87.8, 83.7, 79.4, 72.4, 72.1, 63.4, 54.9, 51.5, 46.3, 
41.1, 33.0, 31.9, 30.2, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 28.7, 
27.4, 27.3, 25.7, 23.7, 22.7, 16.3, 15.7, 14.1, 10.9;  νmax: br. 3524, 
3030, 3063, 2922, 2851, 1732, 1715, 1465, 1107, 733 cm
-1
. 
(b) Palladium hydroxide on activated charcoal (20%  Pd(OH)2-C, 
0.0015 g, 0.15 fold by weight) was added to a stirred solution of 
7g (0.010 g, 0.006 mmol) in dry CH2Cl2 : MeOH (1:1, 2 mL) at 
room temperature under hydrogen atmosphere. The reaction 
mixture was stirred overnight then worked up as before to afford 
the title compound as a thick white oil 8g (0.0069 g, 63%) 
[Found  (M+NH4)
+
: 1401.3546, C90H178NO8 requires: 
1401.3547], [] 21
D
+10.5 (c 0.1, CHCl3 + few drops of CD3OD);
  
δH (400 MHz, CDCl3): 4.89 (1H, s), 4.51 (1H, dd, J 12, 4.0 Hz), 
4.33 (1H, dd, J 12.0, 4.1 Hz), 4.21 – 4.15 (1H, m), 4.07 (1H, br. 
s), 4.02 – 3.95 (1H, m), 3.74 – 3.66 (1H, m), 3.41 (3H, s), 2.90 – 
2.71 (2H, m), 2.56 – 2.48 (1H, m), 2.48 – 2.37 (4H, m, including 
the OH), 2.23 – 1.10 (140H, m), 1.05 (3H, d, J 6.9 Hz), 0.89 (6H, 
t, J 6.8 Hz), 0.70 – 0.61 (2H, m), 0.59 – 0.53 (1H, dt, J 7.9, 3.9 
Hz), -0.33 (1H, br. q, J 5.2 Hz);
 
δC (101 MHz, CDCl3 + few drops 
of CD3OD): 215.0, 174.9, 108.7, 83.8, 80.4, 78.4, 72.8, 63.2, 
54.9, 52.1, 46.3, 41.1, 35.2, 33.0, 31.9, 30.2, 29.7, 29.6, 29.5, 
29.45, 29.4, 29.35, 29.3, 28.7, 27.4, 27.3, 25.4 23.7, 22.7, 16.36, 
15.7, 14.1, 10.9 ; νmax: br. 3436, 2918, 2850, 1731, 1708, 1467, 
1170 cm
-1
. 
 
 
3.12: Methyl 5-O-(2-[(1R)-1-hydroxy-16-[(1R,2S)-2-(20-
methyl-19-oxo- octatriacontyl)cyclopropyl]hexadecyl]- 
hexacosa-noate)-α-D-Araf 8g’ 
(a) Cesium hydrogencarbonate (0.062g, 0.319 mmol) was added 
to a stirred solution of  5  (0.048 g, 0.096 mmol) and (R)-2-{(R)-
1-hydroxy-16-[(1R,2S)-2-((S)-20-methyl-19-oxo-octatriacontyl)-
cyclopropyl]hexadecyl}hexacosanoic acid  (0.080 g, 0.064 
mmol)
42
 in dry DMF : THF (1:5, 4 mL) at room temperature and 
the mixture was stirred at 70 ºC for 2 days, then worked up and 
purified as before to afford methyl 2,3-di-O-benzyl-5-O-(2-[(1R)-
1-hydroxy-16-[(1R,2S)-2-(20-methyl-19-oxooctatriacontyl)-
cyclopropyl]hexadecyl]hexacosanoate)-α-D-Araf as a colourless 
thick oil  7g’ (72 mg, 71%) [Found (M+NH4)
+
: 1581.4467, 
C104H190NO8 requires: 1581.4486], []
23
D
  + 25 (c 0.10, CHCl3) 
which showed δH (400 MHz, CDCl3): 7.42 – 7.27 (10H, m), 4.92 
(1H, s), 4.58 (1H, d, J 12.0 Hz), 4.56 (1H, d, J 11.8 Hz), 4.50 
(1H, d, J 12.0 Hz), 4.47 (1H, d, J 11.8 Hz), 4.34 – 4.26 (2H, m), 
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 9 
4.22 (1H, dt, J 4.6, 9.1 Hz), 3.99 (1H, br. d, J 2.1 Hz), 3.84 (1H, 
dd, J 2.6, 6.4 Hz), 3.68 – 3.58 (1H, m), 3.38 (3H, s), 2.56 – 2.47 
(2H, m, including OH), 2.47 – 2.37 (3H, m), 1.76 – 1.09 (144H, 
m), 1.05 (3H, d, J 6.9 Hz), 0.89 (6H, t, J 6.8 Hz), 0.70 – 0.61 
(2H, m), 0.56 (1H, dt, J 4.0, 8.0 Hz), -0.33 (1H, br. q, J 5.2 Hz); 
δC (101 MHz, CDCl3): 215.2, 175.0, 137.4, 137.2, 128.5, 128.4, 
128.0, 127.9, 127.8, 107.2, 87.8, 83.7, 79.4, 72.4, 72.1, 72.0, 
63.4, 54.9, 51.5, 46.3, 41.1, 35.5, 33.0, 31.9, 30.2, 29.7, 29.67, 
29.6, 29.57, 29.5, 29.46, 29.4, 29.3, 28.7, 27.4, 27.3, 25.8, 23.7, 
22.7, 16.4, 15.8, 14.1, 10.9; νmax: 3457, 3064, 3032, 2921, 2851, 
1717, 1678, 1466, 1101, 755, 697 cm
-1
. 
(b) Palladium hydroxide on activated charcoal (20% Pd(OH)2-C, 
0.01g, 0.15 fold by weight) was added to a stirred solution of  
compound 7g’ (0.066 g, 0.042 mmol) in dry CH2Cl2 : MeOH 
(1:1, 2 mL) at room temperature under hydrogen atmosphere. 
The mixture was worked up and purified as before to afford the 
title compound 8g’ as a colourless thick oil (39 mg, 66%) [Found 
(M+NH4)
+
: 1401.3546, C90H178NO8, requires: 1401.3547], []
23
D
 
+11 (c 0.10, CHCl3) which showed δH (400 MHz, CDCl3 + few 
drops CD3OD): 4.89 (1H, s), 4.51 (1H, dd, J 3.9, 11.9 Hz), 4.32 
(1H, dd, J 4.0, 11.9 Hz), 4.21 – 4.15 (1H, m), 4.07 (1H, br. s), 
3.98 (1H, br. d, J 1.8 Hz), 3.74 – 3.66 (1H, m), 3.41 (3H, s), 2.87 
– 2.67 (2H, m), 2.55 – 2.38 (4H, m), 1.71 – 1.12 (145H, m), 1.05 
(3H, d, J 6.9 Hz), 0.89 (6H, t, J 6.8 Hz), 0.69 – 0.61 (2H, m), 
0.56 (1H, dt, J 4.0, 8.0 Hz), -0.33 (1H, br. q, J 5.2 Hz); δC (101 
MHz, CDCl3 + few drops CD3OD): 215.4, 175.0, 108.7, 83.6, 
80.6, 78.4, 72.8, 63.2, 55.0, 52.3, 50.9, 46.3, 41.1, 35.2, 33.0, 31.9, 
30.2, 29.7, 29.65, 29.6, 29.5, 29.45, 29.41, 29.40, 29.3, 28.7, 27.4, 
27.3, 25.4, 23.7, 22.7, 16.4, 15.8, 14.1, 10.9; νmax: 3405, 2920, 2851, 
1713, 1712, 1466, 1108, 759 cm-1. 
 
3.13: Methyl 5-O-(2-{(1R)-1-hydroxy-17-[(1S, 2R)-2-[(2S)-22-
methyl-21-oxotetracontan-2-yl]cyclopropyl] heptadecyl}hexa- 
cosanoate) α-D-Araf 8h 
(b) Cesium hydrogen carbonate (0.045 g, 0.232 mmol) was added 
with stirring to 5 (0.025 g, 0.050mmol) and (R)-2-{(R)-17-[(1S,2R)-
2-((1S)-1,21-dimethyl-20-oxo-nonatriacontyl)cyclopropyl]-1-
hydroxy heptadecyl}hexacosanoic acid methyl ester (0.043 g, 0.033 
mmol)43 in dry DMF:THF (1:5, 2 mL) at room temperature and 
stirred at 70 ºC for two days, then worked up as before to give methyl 
2,3-di-O-benzyl-5-O-(2-{(1R)-1-hydroxy-17-[(1S,2R)-2-[(2S)-22-
methyl-21-oxotetra-contan-2-
yl]cyclopropyl]heptadecyl}hexacosanoate) α-D- Araf 7h as a thick 
colorless oil (0.050 g, 92%) [Found (M+Na)+:1628.4539, 
C107H192NaO8 requires: 1628.4509], []
21
D
+16.8   (c 0.1, CHCl3); 
 δH 
(400 MHz, CDCl3): 7.40 – 7.27 (10H, m), 4.92 (1H, s), 4.58 (1H, d, 
J 12.0 Hz), 4.56 (1H, d, J 12 Hz), 4.53 (1H, d, J 12 Hz), 4.48 (1H, d, 
J 12 Hz), 4.33 – 4.28 (2H, m), 4.22 (1H, dt, J 10.7, 4.6 Hz), 3.99 (1 
H, br d, J 1.9 Hz), 3.84 (1H, dd, J 6.4, 2.6 Hz), 3.68 – 3.58 (1H, dt, J 
7.6, 5.2 Hz), 3.38 (3H, s), 2.58 – 2.47 (2H, m), 2.47 – 2.38 (3H, 
m), 1.72 – 1.13 (146H, m), 1.06 (3H, d, J 6.9 Hz), 0.89 (9H, 
including a triplet J 7.5 Hz), 0.72 – 0.61 (1H, m), 0.50 – 0.41 
(1H, m), 0.24 – 0.08 (3H, m); δC (101 MHz, CDCl3): 215.2, 
175.0, 137.5, 137.3, 128.5, 128.4, 128.0, 127.9, 127.8, 107.2, 
87.8, 83.7, 79.4, 72.4, 72.1, 63.5, 54.9, 51.5, 46.3, 41.1, 38.1, 
37.4, 35.5, 34.5, 33.0, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 27.4, 
27.35, 27.3, 26.1, 25.7, 23.7, 22.7, 19.7, 18.6, 16.3, 14.1, 10.5 ; 
νmax: br. 3524, 3064, 3031, 2923, 2853, 1737, 1715, 1465, 1107, 
734 cm
-1
.  
(b) Palladium hydroxide on activated charcoal (20%  Pd(OH)2-C 
, 0.0015 g, 0.15 fold by weight) was added to a stirred solution of 
7h (0.010 g, 0.006 mmol ) in dry CH2Cl2 : MeOH (1:1, 2 mL) at 
room temperature under hydrogen atmosphere. The mixture was 
stirred overnight then worked up as before to afford the title 
compound as a thick colorless oil 8h (0.010 g, 80%) [Found  
(M+Na)
+
: 1448.3585, C93H180NaO8 requires: 1448.3570], [] 21D
+ 13  (c 0.10, CHCl3); δH (400 MHz, CDCl3): 4.89 (1H, s), 4.49 
(1H, dd, J 12, 4 Hz), 4.33 (1H, dd, J 12, 4.2 Hz), 4.21 – 4.16 (1H, 
m), 4.09 (1H, d, J 6.8 Hz), 4.01 – 3.95 (1H, m), 3.75 (1H, d, J 5.4 
Hz), 3.73 – 3.65 (1H, m), 3.41 (3H, s), 2.61 – 2.47 (1H, m), 2.46 
– 2.28 (5H, m), 1.72 – 1.15 (146H, m), 1.06 (3H, d, J 6.9 Hz), 
0.89 (9H, including a triplet at 0.89 with J 7.4 Hz), 0.76 – 0.61 
(1H, m), 0.51 – 0.39 (1H, m), 0.26 – 0.05 (3H, m); δC (101 MHz, 
CDCl3): 215.3, 174.9, 108.7, 83.8, 80.4, 78.8, 78.4, 72.8, 54.9, 
52.2, 46.3, 44.5, 41.1, 38.1, 37.4, 35.2, 34.5, 33.0, 31.9, 30.0, 
29.7, 29.6, 29.5, 29.3, 27.3, 26.1, 25.4, 23.71, 22.7, 19.7, 18.6, 
16.3, 14.1, 10.5; νmax: br. 3467, 2917, 2849, 1731, 1713, 1467, 
1050,720 cm
-1
. 
 
3.14: Methyl 5-O-(2-{(R)-1-hydroxy-12-[(1S, 2R) -2-[14-[(1S, 
2R)-2-eicosylcyclopropyl]tetradecyl]cyclopropyl]dodecyl}- 
hexacosanoate) α-D-Araf 8i 
 
(a) Cesium hydrogen carbonate (0.089g, 0.46 mmol) was added 
to a stirred solution of 5 (0.049 g, 0.098 mmol) and (R)-2-((R)-1-
hydroxy-12-{(1S,2R)-2-[14-((1S,2R)-2-eicosylcyclopropyl)tetradec-
yl]cyclopropyl}dodecyl)hexacosanoic acid (0.075 g, 0.065 mmol)
37
 
in dry DMF:THF (1:5, 2 mL) at room temperature and then 
stirred at 70º C for two days. Work up as before gave methyl 2,3-
di-O-benzyl-5-O-(2-{(R)-1-hydroxy-12-[(1S,2R)-2-[14-[(1S,2R)-
2-eicosylcyclopropyl]tetradecyl]cyclopropyl]dodecyl}hexacosan-
oate) α-D-Araf 7i as a thick colorless oil (0.084 g, 87%) [Found 
(M+Na)
+
: 1486.3173, C98H174NaO7 requires: 1486.3152],  [] 21D
+31 (c 0.10, CHCl3); δH (400 MHz, CDCl3): 7.39 – 7.28 (10H, 
m), 4.92 (1H, s), 4.58 (1H, d, J 12 Hz), 4.56 (1H, d, J 12 Hz), 
4.51 (1H, d, J 12 Hz), 4.48 (1H, d, J 12 Hz), 4.32 – 4.28 (2H, m), 
4.25 – 4.19 (1H, m), 3.99 (1H, br d, J 2.3 Hz), 3.84 (1H, dd, J 
6.4, 2.6 Hz), 3.68 – 3.59 (1H, m), 3.38 (3H, s), 2.52 (1H, d, J 8.3 
Hz), 2.44 (1H, dt, J 9.3, 5.5 Hz), 1.62 – 1.03 (134H, m), 0.89 
(6H, t, J 6.7 Hz), 0.72 – 0.62 (4H, m), 0.61 – 0.52 (2H, dt J 8, 4 
Hz), -0.32 (2H, br. q J  5.1 Hz); δC (101 MHz, CDCl3): 175.0, 
137.4, 137.2, 128.5, 128.4, 128.0, 127.9, 127.89, 127.8, 107.2, 
87.8, 83.7, 79.4, 72.4, 72.2, 72.1, 63.5, 54.9, 51.5, 35.5, 31.9, 
30.55, 30.5, 30.45, 30.44, 30.4, 30.35, 30.3, 30.28, 30.2, 30.18, 
30.1, 30.0, 29.9, 29.7, 29.6, 29.5, 29.4, 29.3, 29.29, 29.2, 29.1, 
29.03, 29.0, 28.7, 28.6, 27.4, 25.7, 22.68, 22.6, 15.7, 14.1, 10.9 ; 
νmax: 3479, 3065, 2989, 2919, 2849, 1733,1607, 1494, 718 cm
-1
. 
(b) Palladium hydroxide on activated charcoal (20% Pd(OH)2-C , 
0.0087 g , 0.15 fold by weight) was added to a stirred solution of 
7i (0.058g, 0.039 mmol) in dry CH2Cl2 : MeOH (1:1, 2 mL) at 
room temperature under hydrogen atmosphere. The mixture was 
stirred overnight then worked up as before to afford the title 
compound as a thick colourless oil 8i (0.040 g, 80%) [Found  
(M+Na)
+
: 1306.2201, C84H162NaO7  requires: 1306.2213], [] 23D
+ 12 (c 0.10, CHCl3);
  
δH (400 MHz, CDCl3 + few drops of 
CD3OD): 4.89 (1H, s), 4.47 (1H, dd, J 11.8, 4.2 Hz), 4.37 (1H, 
dd, J 11.9, 4.1 Hz), 4.20 – 4.14 (1H, m), 4.07 (1H, br. s), 3.98 
(1H, br. s), 3.79 – 3.67 (1H, m), 3.40 (3H, s), 3.06 (2H, br. s), 
2.45 (1H, dt, J 10.1, 5.0 Hz), 1.90 – 1.83 (1H, m), 1.63 – 1.07 
(134H, m), 0.89 (6H, t, J 6.8 Hz), 0.71 – 0.61 (4H, m), 0.60 – 
0.49 (2H, dt, J 8, 4 Hz), -0.33 (2H, br. q J 5.2 Hz); δC (101 MHz, 
CDCl3): 175.0, 108.7, 83.4, 80.7, 78.4, 72.8, 63.2, 54.9, 52.4, 
35.1, 31.9, 30.4, 30.2, 30.18, 29.7, 29.68, 29.6, 29.5, 29.48, 29.4, 
29.35, 29.3, 28.7, 27.4, 25.4, 22.6, 15.7, 14.1, 10.9 ; νmax: 3436, 
390, 2918, 2850, 1733, 1467, 1455, 1050 cm
-1
. 
3.15: The ELISA assay 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Tetrahedron 10 
ELISA were carried out on 96-well flat-bottomed polystyrene 
micro-plates.  Antigens were dissolved in hexane to give an 
antigen solution of concentration 15 µg/ml.  50 µl of this solution 
was added to each well, and the solvent was left to evaporate at 
room temperature. Control wells were coated with hexane (50 µl 
/ well) only.  Blocking was done by adding 400 µl of 0.5 % 
casein/PBS buffer (pH 7.4) to each well, and the plates were 
incubated at 25 ºC for 30 min.  The buffer was aspirated and any 
excess buffer was flicked out until the plates were dry.  Serum (1 
in 80 dilution in casein/PBS buffer) (50 µl / well) was added and 
incubated at 25 ºC for 1 h.  The plates were washed with 400 µl 
casein/PBS buffer 3 times using an automatic washer, and any 
excess buffer was flicked out onto a paper towel until dry.  
Secondary antibody (anti-human IgG (Fc specific) peroxidise 
conjugated antibody produced in goat (Aldrich) (diluted to a 
concentration of 1:2000 in casein/PBS buffer) (50 µl / well) was 
added, and incubated at 25 ºC for 30 minutes.  The plates were 
again washed 3 times with 400 µl casein/PBS buffer using an 
automatic washer, and any excess buffer was again flicked out.  
OPD substrate (50 µl / well) (o-phenylenediamine (1 mg / ml) 
and H2O2 (0.8 mg / ml) in 0.1 M citrate buffer) was then added, 
and the plates were incubated for a further 30 minutes at 25 ºC.  
The colour reaction was terminated by adding 2.5 M H2SO4 (50 
µl / well), and the absorbance was read at 492nm. 
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1. Introduction 
The mycobacterial cell wall has a complex structure made up of 
lipids, glycolipids, polysaccharides and proteins.
1 
There are four 
major components: peptidoglycan (PG), mycolyl-arabinogalactan 
(mAG), lipoarabinomannan (LAM) and extractable lipids.
2 
The 
mycolyl-arabinogalactan (mAG) complex is the largest 
component structure and acts as a permeability barrier that 
prevents passage of antibiotics. It forms from cross bonding 
between both D-arabinofuranosyl (Araf) and-galactofuranosyl 
(Galf ) with a long chain (C70-C90), α-alkyl branched β-
hydroxylated fatty acid, ‘mycolic acid’; carbohydrate (Araf) and 
(Galf) are bound to peptidoglycan in the cell wall by an α-L-
rhamnopyranosyl-(1→3)-2-acetamido-2-deoxy-α-D-gluco-
pyranosyl phosphate disaccharide. The galactan part is linear and 
composed of alternating β-(1→5) and β-(1→6) galactofuran 
residues. Galactan and arabinan are bonded from C-5 of the β-
(1→6) link.
3-6
 Both galactosyl and arabinosyl units in mAG are 
in a furanose form, less stable thermodynamically than the 
pyranose form.
7
 It is believed that this plays a large role in raising 
the flexibility of the polysaccharide and making the mycolic 
acids (MAs) pack strongly by van de Waals interaction. Thereby, 
the structure of the cell wall has extremely low permeability and 
this provides the organism with high protection from drugs and 
from its environment.
1
 Therefore, studying and understanding 
mAG biosynthesis is an important strategy for developing new 
anti-tuberculosis drugs. Indeed, isoniazid and ethambutol, two of 
the standard antibiotics, target mAG biosynthesis; ethambutol 
inhibits arabinosyltransferases which contribute to the 
biosynthesis of the arabinan part of the polysaccharides while 
isoniazid inhibits mycolic acid biosynthesis.
8
 
It is approaching a century since Anderson began his ground 
breaking studies of the lipid components of mycobacteria, 
leading eventually to the characterization of MAs. These were 
shown to be high-molecular weight hydroxy acids, with an 
experimental formula of C88H172O4 or C88H176O4 which were very 
hard to purify and not possible to crystallize.
9,10 
The long alkyl 
branch on the α-position and hydroxyl groups in β-position in 
MAs was proved by Asselineau in 1950.
11
 In brief, MAs can 
defined as a complex group of long chain fatty α-alkyl β-alkyl 
hydroxyl fatty acids (Figure 1).
12,13
 
 
Figure 1: Generalised mycolic acid structure 
The proximal group Y is generally a cis- alkene or cyclopropane, 
or a trans-alkene or cyclopropane with a further methyl 
substituent on the adjacent carbon distal from the hydroxyl acid. 
The distal group X is normally a cis-cyclopropane (α-MAs), a –
(CHMeCHOMe)- (methoxy MAs)  or a –(CHMeCO)- fragment 
(keto MAs).  Mixtures extracted from mycobacteria comprise 
many individual MA containing a range of functional groups X 
and Y (Figure 1) and but each also of several chain lengths.
14
 
Anderson & Geiger in 1937 claimed the first extraction of 
arabino-mycolate from the cell wall of Mycobacterium bovis 
using natural organic solvent.
15
 Some fifty years ago, the 
isolation of arabinose 5-mycolate by extraction of the cell walls 
of various mycobacteria under acidic conditions was reported.
16-
22
 More recently, mass spectrometry and NMR have provided 
powerful tools for the analysis of such molecules.
23 
Azuma and 
Yamamura in 1962 isolated arabinomycolate as a D-arabinose-5-
mycolate and proved it was toxic to mice.
17 
Inflammatory 
reactions similar to that observed after inoculation of live BCG 
were induced in the lungs by trehalose monomycolate and 
dimycolate (TMM and TDM) or glucose monomycolate (GMM) 
isolated from BCG. However, the toxic reactions caused by 
glycerol monomycolate (GroMM) and arabinose mono-mycolate 
were characterized by an acute inflammatory process.
24
 
 
In 2006, the preparation of a tetramycolyl pentaarabinose using a 
complex natural mixture of MAs was described.
25
 However, only 
in 2010 were structural studies of the composition of the 
arabinose mycolates of the cell wall of M. bovis reported. A two-
layer acid hydrolysis gave a number of fractions. One of these 
was a penta-arabinose tetramycolate, one was an arabinose 
mono-mycolate, while the others were hexa-arabinose, hepta-
arabinose and octa-arabinose tetramycolates. The mycolic acid 
methyl esters released from each of these showed a mass 
spectrometric pattern almost identical to the methyl esters 
obtained by hydrolysis of the original cell wall. A comparison of 
the penta-arabinose tetramycolate and arabinose monomycolate 
with samples prepared by combining a mixture of natural MAs 
with arabinose was reported.
26
 Ishiwata et al reported the 
synthesis of a series of mono-, di- and tetra-arabinomycolates 
found in the terminal position of cell wall skeleton of bacillus 
Calmette Guerin from M. bovis, by using natural mycolic acid 
mixtures extracted from the cell wall. They proved the biological 
activity for synthesized compounds in a tumor necrosis factor 
alpha (TNF-α) secretion-inducing assay; all the compounds 
showed strong TNF-α inducing activity in vitro.
25 
The 
mechanism of the activity of arabino-mycolate is not clear.
22
 
Synthetic arabino-mycolates induce the production of TNF-α in 
murine macrophage cell lines at an intensity similar to BCG-
CWS (cell wall skeleton). However the immunological activity 
of natural arabino-mycolates isolated from BCG has not been 
investigated, probably due to the complexity of the molecule.  
Arabino-mycolates obtained by acid hydrolysis from CWS 
(SMP-105) of M. bovis BCG Tokyo 172 strain consisted mainly 
of mono-arabinose mono-mycolate, pentaarabinose tetra-
mycolate and hexa-arabinose tetramycolate fractions. Arabino-
mycolates significantly induced TNF-α production and enhanced 
delayed type hypersensitivity (DTH) reactions against inactivated 
tumour cells. Arabino-mycolates-induced TNF-α production was 
completely dependent on TLR2 and MyD88 pathways. Thus 
isolated natural arabino-mycolates possess potent adjuvant 
immunostimulatory activity.
27
   
Intra-tumor injections of extracts of Re mutant Salmonella 
typhimurium in combination with TDM or arabinose mycolate 
were highly effective in producing regression of tumors in guinea 
pigs. Similar extracts from M. bovis strain BCG and strain AN5 
in combination with TDM also possessed tumor-regressive 
activity. The activity was reduced when the arabinose mycolate 
was substituted for the TDM. An extract of Coxiella burnetii, in 
combination with either TDM or arabinose mycolate was also 
active. Intracutaneous administration of Re glycolipid or aqueous 
extracts from BCG in combination with trehalose or arabinose 
mycolates did not produce life-threatening, clinical signs of 
toxicity in young mice. If additional toxicity studies demonstrate 
that adverse side effects can be satisfactorily controlled, these 
water soluble extracts may prove beneficial in the treatment of 
spontaneous tumors of humans and other animals.
28.29 
The 
adjuvant activity of cell wall skeletons (mycolic acid-arabino-
galactan-mucopeptide) prepared from the cells of mycobacteria, 
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 3 
nocardia and corynebacteria was examined in vivo in mice and 
guinea pigs. The cell wall skeletons of M. bovis BCG (BCG-
CWS), Nocardia asteroides 131 and Corynebacterium 
diphtheriae PWC suspended in Freund's incomplete adjuvant 
(FIA) as water-in-oil emulsions showed potent adjuvant activity 
on the formation of circulating antibody and cell-mediated 
immunity to bovine serum albumin (BSA), sheep erythrocytes 
(SRBC) and sulfanylazo-bovine serum albumin (SA-BSA) in 
mice and guinea pigs. After acetylation or acid treatment, BCG-
CWS retained its adjuvant activity, but the activity of BCG-CWS 
was destroyed completely by alkaline treatment. The cell wall 
constituents, arabinose-mycolate and arabino-galactan, prepared 
from BCG-CWS showed no adjuvant activity.
30
 
Few studies
 
of arabinose mycolates have been carried out and 
little is known of the effect of structure on the 
immunostimulatory activity of arabino-mycolates in activating 
macrophages.
6
 However, D-arabinose-5-mycolate, purified from 
bound lipids of the cell-wall skeleton of M. bovis BCG may be 
prominent structure for recognition by host immunity.
6
  
 
 However, it is now clearly established that, in the case of free 
MAs, the detailed structure controls their effects on a range of 
cytokines and chemokines and that some lead to inflammatory 
reactions on intratracheal instillation in mice, while others lead to 
the formation of foam cells.
31
 We now report the synthesis of a 
set of arabinose esters of stereochemically defined synthetic 
MAs, as well as those of some simple fatty acids.  
 
2a Results and discussion: synthesis of arabinose mycolates 
According to literature procedures, D-(-)-arabinose 1 was treated 
with HCl (0.22 M) freshly prepared by addition of acetyl chloride 
to anhydrous methanol at 0 ºC working up with pyridine rather 
than ammonium carbonate,
32 
to give methyl-α,β-D-arabino 
furanoside with predominant formation of the α-anomer (α-D/β-D 
3:2).
33,34
 In order to isolate these two anomers, in situ  tritylation 
of this mixture followed by column chromatography  gave 
methyl 5-O-trityl α-D-Araf 2 (45%) and 5-O-trityl β-D-Araf 3 
(30%). Compound 2 was benzylated to protect the two secondary 
hydroxyl groups by using benzyl bromide and sodium hydride in 
dry DMF then the trityl group was removed from the primary 
hydroxyl group by hydrolysis in 80% AcOH, affording 
compound 4 (Scheme 1).
25,34
   
 
 
Scheme 1. Reagents and conditions: (i) HCl, CH3OH; (ii) Trityl chloride, 
DMAP, pyridine, 0 ºC/R.T., then 70 ºC 4 h, 45% from α-anomer; (iii) a: 
NaH, BnBr, DMF, 0 ºC/R.T. 2 h, b: 80% AcOH, 75 ºC for 4 h, 78%; (iv) 4-
toluenesulfonyl chloride, DMAP, pyridine, 90%. 
 
 
According to the literature,
25
 direct esterification between the 
primary hydroxyl group of Araf and a carboxyl group in natural 
mycolic acid mixtures was achieved in a low yield (30%), while 
activating the sugar as a tosylate raised the yield to 79%. 
Therefore, the hydroxyl group in the compound 4 was tosylated 
by reaction with p-toluenesulfonyl chloride in dry pyridine and 
catalytic 4-dimethylaminopyridine (DMAP) in dry CH2Cl2 at 0 
ºC to afford the tosylate 5. Surprisingly, esters of arabinose with 
simple fatty acids do not appear to have been reported. In a 
model experiment, compound 4 was therefore first condensed 
with behenic acid using DMAP and N,N-dicyclohexylcarbodi-
imide in dry CH2Cl2 to give compound 7a  in 80% yield.
36
 This 
was then hydrogenolysed in the presence of Pd(OH)2 and under a 
hydrogen atmosphere to give the behenyl arabinose 8a. 
Compound 5 was also reacted with palmitic acid by an alkylative 
esterification using cesium hydrogen carbonate in dry DMF: THF 
at 70 
0
C,
25
 to give compound 7b; this was then debenzylated to 
give the compound 8b. In the same way, compound 5 was 
reacted with oleic acid to give the compound 7c; hydrogenolysis 
in the presence of Pd(OH)2 under a hydrogen atmosphere gave 
the corresponding stearyl arabinose, in which the double bond 
was also saturated. However, deprotection with boron trichloride 
in dichloromethane and methanol gave the oleoyl derivative 8c. 
A series of synthetic MAs was then reacted with the compound 5 
by alkylative esterification using cesium hydrogen carbonate as 
in Scheme 2. Firstly, the methoxy cis-cyclopropane mycolic acid 
6d,
37
 gave compound 7d, which was then debenzylated using 
hydrogen  and Pd(OH)2 catalyst to give the arabinose ester 8d. 
This was achieved with no loss of the cyclopropane group, on the 
basis of the proton and carbon NMR spectra. Although the 
absolute stereochemistry of the cis-cyclopropane unit in MAs 
remains unproven, this compound contains the stereochemistry 
that appears likely, based on a common intermediate leading to 
the different classes of mycolic acid.
38
 The 22 carbon length of 
the α-chain is typical of mycobacteria such as Mycobacterium 
kansasii.
39
 Condensation of methoxy-cis-cyclopropane mycolic 
acid 6e,
37
 having a twenty two carbon chain in the α-position, and 
the opposite absolute cis-cyclopropane stereochemistry, one 
stereoisomer of which is present in M. kansasii, led to compound 
7e. On hydrogenolysis as above, this gave compound 8e. In the 
same way, esterification of methoxy-cis-cyclopropane mycolic 
acid 6f,
40
 with a twenty four carbon chain at the α-position, a 
stereoisomer of which is a major component of M. tuberculosis 
methoxy-MA,
39
  but the opposite cyclopropane stereochemistry 
to 6d gave compound 7f, which on hydrogenolysis led to 
compound 8f.  
The same procedure was repeated to prepare the arabino ester 
compounds for the keto cis-cyclopropane mycolic acid 6g,
37
 with 
a C22 alkyl chain in the α-position; this was used as the epimeric 
mixture at the carbon adjacent to the ketone.  This produced 
compound 7g which on debenzylation gave the arabinose ester 
8g. Ester 8g’, with the normal C24 M. tuberculosis α-chain length, 
was also obtained from 6g’.
41
 In the same way the arabinose ester 
8h, from the keto trans-cyclopropane mycolic acid 6h,
42
 again 
epimeric adjacent to the ketone,  was obtained in good yield. 
Finally, the α-mycolic acid 6i,
43,44  
was esterified
  
to give 
compound 7i and then debenzylation to give 8i.  
The yields for each of these coupling steps and deprotections are 
given in Table 1. All the products were characterized by accurate 
mass MALDI-MS, proton and carbon NMR and the spectra are 
presented as Supplementary Information. 
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R =   stearate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
R 7 (%) 8 (%) 
a 80 81 
b 76 88 
c 83 64 
d 77 79 
e 75 65 
f 80 76 
g 80 63 
g’ 71 66 
h 92 80 
i 87 80 
Table 1: Yields for arabinose esters 
 
2b. Assessment of arabinose mycolates as antigens 
It is known that both trehalose esters of natural MAs, and the free 
acids themselves are antigenic to antibodies in the serum of 
patients infected with tuberculosis (TB).
45,46 
As an initial study of 
the biological properties of the unique arabinose mycolates 
prepared in this work, their antigenicity to 64 serum samples 
taken from a Gambian population was determined using a 
standard  enzyme-linked immunosorbent assay (ELISA). The 
samples, provided by the World Health Organisation from the 
TDR TB Specimen Bank,
47
 were all from individuals with 
symptoms of suspected tuberculosis. Nine were diagnosed as 
having active TB using a range of clinical and biochemical 
assays; 55 as were diagnosed as not having active TB. The 
categorization was carried out using standard WHO protocols. 
The assay used an IgG(Fc) conjugated secondary antibody to 
detect the disease antibody – antigen interaction based on the 
resulting absorbance at 492 nm. The results are summarized in 
Table 2. This shows the median absorbance for active TB and no 
active TB samples, the area under the curve (AUC) for a 
Receiver Operating Characteristic (ROC) analysis of the data for 
each antigen, the cut-off response set for a positive response for 
each antigen in the assay, and the resulting sensitivity (% of 
active TB diagnosed samples giving a response above the assay 
cut-off) and specificity (% of no active TB samples giving a 
response below the cut-off value). 
 
  
 
  R=  CH3(CH2)20  a,  CH3(CH2)14  b  R =   c               
 
 
R=       d 
 
R=       e      
 
R=   f      
R=    g n = 21 
       g’ n= 23    
R=       h      
R=     i      
 
Scheme 2: Synthesis of arabinose esters 
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 5 
 
7d 7e 7f 7g 7h 7i 
Median 
active TB 0.64 0.40 0.78 0.50 0.48 1.18 
 
Median no 
active TB 0.39 0.33 0.46 0.44 0.45 0.52 
 
 
     ROC AUC .85 .69 .87 .69 .67 .95 
 
Cut-off for 
‘active’ in 
assay >.35 >.27 >.45 >1.00 >.25 >.7 
 
Active TB 
samples above 
the cut-off 9 9 9 1 9 9 
 
No active TB 
samples above 
the cut-off 18 29 20 2 45 11 
  
     Sensitivity 100 100 100 100 100 100 
Specificity 
        
67 47 64    20 18 80 
 
Table 2. Responses for a set of 64 human serum samples from 
Gambia (9 diagnosed with active TB, 55 with no active TB) to 
synthetic arabinose mycolates coated as antigens on ELISA 
plates, using IgG(Fc) secondary antibody conjugate to determine 
the binding. The closer the ROC AUC is to 1, the higher the 
predictive value of the assay. 
 
This shows that the six synthetic arabinose mycolates are 
detected to a different degree by antibodies in the serum of 
patients infected with active tuberculosis; in some cases the 
response is essentially no different between active TB and no 
active TB samples, whereas in others, such as 7i, the assay result 
correlates well with the clinical diagnosis. The active TB status 
had been  determined using a range of standard assays employed 
by the WHO, including being smear and culture positive; the no 
active TB samples were all from patients showing some of the 
symptoms of TB, but diagnosed using the same methods as not 
having active TB, and being both smear and culture negative. 
Although this is a very small sample set, it is interesting that the 
highest distinction between active TB and no active TB sets is 
given with the arabinose mycolates 7d and 7i which probably 
represent the natural stereochemistries of methoxy- and α-
mycolates. Work is on-going to validate these results on a larger 
sample set. 
The effects of selected examples of the above synthetic arabinose 
mono-mycolates on the Mincle receptor in M. tuberculosis will 
be described elsewhere.
48
 
3. Experimental section 
Chemicals used were obtained from commercial suppliers 
(Sigma, Aldrich, and Alfa Aeser) or prepared from them by the 
methods described. Solvents which were required to be dry, e.g. 
ether, tetrahydrofuran were dried over sodium wire and 
benzophenone under nitrogen, while dichloromethane and 
HMPA were dried over calcium hydride. All reagents and 
solvents used were of reagent grade unless otherwise stated. 
Organic solutions were dried over anhydrous magnesium sulfate. 
Silica gel (Merck 7736) and silica gel plates used for column 
chromatography and thin layer chromatography were obtained 
from Aldrich; separated components were detected using 
variously UV light, I2 and phosphomolybdic acid solution in IMS 
followed by charring.   Infra-red (IR) spectra were carried out on 
a Perkin-Elmer 1600 F.T.I.R. spectrometer as liquid films or KBr 
disc (solid). Melting points were measured using a Gallenkamp 
melting point apparatus. NMR spectra were carried out on a 
Bruker AC250 or Advance 400 spectrometer. [α]D values were 
recorded in CHCl3 on a POLAAR 2001 optical activity 
polarimeter. Low resolution mass spectra were recorded on a 
Bruker matrix-assisted laser desorption/ ionisation-time of flight 
mass spectrometry (MALDI-TOF MS) values are given plus 
sodium. Accurate mass measurements were carried out by the 
EPSRC UK National Mass Spectrometry Facility at Swansea 
University. 
3.1: Methyl 5-O-trityl-α-D-Araf 2 
Freshly prepared HCl solution in MeOH (resulting from mixing 
acetyl chloride (2 mL) in MeOH (30 mL) at 0 ºC) was added to a 
stirred solution of D-(-)-arabinose (5.0 g, 33 mmol) in anhydrous 
MeOH (100 mL). Stirring was continued overnight at room 
temperature, when a clear solution was obtained. The mixture 
was neutralized by adding pyridine to pH 7 – 8, and the solid was 
filtered and washed with MeOH (10 mL). The solvent was 
evaporated to give a residue which was purified by column 
chromatography eluting with chloroform: acetone (3:5) to give a 
colourless oil, methyl–α,β-D-Araf (4.3 g, 78%). Trityl chloride 
(6.42 g, 23.0 mmol) and 4-(dimethylamino)pyridine (2.57 g, 21.0 
mmol) were added to a stirred solution of methyl-α,β-D-Araf  
(3.12 g, 19.0 mmol) in anhydrous pyridine (60 mL) and the 
mixture was stirred at room temperature overnight then heated on 
oil bath at 70 ºC for 4 h. The mixture was cooled to room 
temperature and poured into ice/water (300 mL). The organic 
phase was separated and the aqueous phase was extracted with 
ethyl acetate (3 × 100 mL). The combined organic layers were 
washed with aq. NaHCO3 solution (5%, 100 mL), dried and the 
solvent was evaporated. The residue was purified by column 
chromatography eluting started from 10% to 50% hexane/ethyl 
acetate gave the title compound as a colorless oil 2 (3.3 g, 45%) 
and 5–O-trityl-β-D-Araf 3 (2.3 g, 30%). The mixture of anomers 
showed δH (400 MHz, CDCl3), δC (125 MHz, CDCl3) and vmax 
identical to the literature.
33.34 
 
 
3.2: Methyl 2,3-di-O-benzyl-α-D-Araf 4 
A solution of 2 (3.20 g, 7.88 mmol) in dry DMF (80 mL) was 
added dropwise to a stirred suspension of NaH (0.85 g) (60% 
w/w, dispersion in mineral oil, washed with petrol three times) at 
room temperature under nitrogen. The mixture was stirred for 30 
min. then benzyl bromide (2.5 mL, 3.6 g, 21.0 mmol) in dry 
DMF (50 mL) was added. The mixture was stirred at room 
temperature for 20 h and then quenched by slow addition of 
water (15 mL) and diluted with ether (25 mL). The organic layer 
was separated and the aqueous layer was extracted with ether (2 
× 100 mL). The combined extracts were washed with water (50 
mL), brine (50 mL), dried and evaporated under reduced 
pressure. Aqueous acetic acid (80%, 30 mL) was added to the 
crude product and the mixture was stirred and heated at 75 ºC for 
4 h, then diluted with water (20 mL) and ether (20 mL) and the 
organic layer was separated and the aqueous layer extracted with 
ether (2 × 100 mL). The combined organic layers were washed 
with water (50 mL), sat. aq. NaHCO3 (50 mL) and brine (50 mL), 
dried and the solvent was evaporated. Column chromatography 
eluting with petrol/ethyl acetate (7:3) gave the title compound as 
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a colorless oil 4 (2.12 g, 78%) [MALDI-Found (M+Na)
+
: 
367.3; C20H24NaO5, requires: 367.1], [] 22D +89 (c 0.10, CHCl3) 
[lit.
26
 []
24
D +83.2 (c 1.14, CHCl3)], which showed δH (400 MHz, 
CDCl3): 7.40 – 7.28 (10H, m), 4.95 (1H, s), 4.61 (1H, d, J 12.0 
Hz), 4.54 (1H, d, J 12 Hz), 4.53 (1H, d, J 12 Hz), 4.50 (1H, d, J 
12 Hz), 4.18 – 4.12 (1H, m), 4.02 – 3.96 (2H, m), 3.85 (1H, dd, J 
12.1, 2.8 Hz), 3.65 (1H, dd, J 12.1, 4.1 Hz), 3.40 (3H, s), 2.93 
(1H, br. s); δC (101 MHz, CDCl3): 137.6, 137.2, 128.4, 128.4, 
127.9, 127.8, 127.79, 127.7, 107.3, 87.6, 82.5, 82.2, 72.3, 71.8, 
62.1, 54.8;  νmax: 3466 br., 3089, 3064, 3031, 2925, 1725, 1605, 
1454, 739 cm
-1
. All data were identical to the literature.
25,34
  
 
3.3: Methyl 2,3-di-O-benzyl-5-O-p-toluensulfonyl-α-D-Araf 5 
p-Toluenesulfonyl chloride (0.60 g, 3.14 mmol) was added to a 
stirred solution of 4 (0.50 g, 1.45 mmol), pyridine (0.96 g, 
0.98mL,  12.4 mmol) and DMAP (0.10g, 0.81 mmol) in dry 
CH2Cl2 (5 mL) at 0 ºC. The mixture was stirred at room 
temperature for 16 h then diluted with ethyl acetate (10 mL), the 
organic layer was separated and the aqueous layer was re-
extracted with ethyl acetate (2 × 100 mL). The combined organic 
layer were washed with water (50 mL), brine (50 mL), dried and 
the solvent was evaporated. The residue was purified by column 
chromatography eluting with hexane/ethyl acetate (4:1) affording 
the title compound as a colorless oil 5 (0.65 g, 90%), [] 23
D
+55 
(c 0.10, CHCl3) [lit.
25
 [] 27
D
+57.0 (c 0.40, CHCl3)], which 
showed δH (400 MHz, CDCl3): 7.77 (2H, d, J 8.2 Hz), 7.41 – 
7.25 (12H, m), 4.85 (1H, s), 4.56 – 4.38 (4H, m), 4.22 – 4.15 
(1H, m), 4.12 (2H, br d, J 4.6 Hz), 3.94 (1H, br d, J 2.6 Hz), 3.81 
(1H, dd, J 5.9, 2.7 Hz), 3.33 (3H, s), 2.42 (3H, s); δC (101 MHz, 
CDCl3): 144.8, 137.3, 137.2, 132.7, 129.7, 128.4, 128.0, 127.9, 
127.89, 127.8, 127.79, 107.4, 87.5, 82.8, 79.2, 72.2, 71.9, 68.8, 
55.1, 21.6; νmax: 3064, 3032, 2916, 1741, 1454, 1365, 1177, 698 
cm
-1
. All data were identical to the literature.
25
  
 
3.4: Methyl 5-O-behenoyl-α-D-Araf 8a 
(a) A solution of N,N`-dicyclohexylcarbodimide (0.089 g, 0.432 
mmol) in dry CH2Cl2 (1 mL) was added dropwise to a stirred 
solution of 4 (0.10g, 0.29 mmol), DMAP  (0.042 g, 0.343 
mmol) and behenic acid (0.10 g, 0.29 mmol) in dry CH2Cl2 (1 
mL) at 0 ºC under nitrogen. The mixture was stirred for 30 min. 
then  the precipitate of dicyclohexyl urea was filtered off and 
washed with CH2Cl2 (10 mL), the solvent was evaporated and 
the residue was purified by column chromatography eluting 
with hexane/ethyl acetate (10:1) to afford methyl 2,3-di-O-
benzyl-5-O-behenoyl-α-D-Araf
31
 as a colorless oil  7a (0.15 g, 
80%) [MALDI-Found (M+Na)+: 689.5, C42H66NaO6 requires: 
689.4], [] 24
D
+40 (c 0.10, CHCl3), which showed  δH (500 
MHz, CDCl3): 7.41 – 7.28 (10H, m), 4.95 (1H, s), 4.59 (1H, d, J 
12.0 Hz), 4.57 (1H, d, J 12 Hz), 4.52 (1H, d, J 12 Hz), 4.49 (1H, 
d, J 12 Hz), 4.29 (1H, dd, J 11.3, 2.8 Hz), 4.24 – 4.15 (2H, m), 
4.01 (1H, dd, J 2.9, 1.1 Hz), 3.84 (1H, dd, J 6.3, 2.9 Hz), 3.40 
(3H, s), 2.33 – 2.26 (2H, m), 1.64 – 1.52 (2H, m), 1.34 – 1.18 
(36H, m), 0.89 (3H, t, J 6.9 Hz); δC (101 MHz, CDCl3): 173.6, 
137.5, 137.4, 128.45, 128.43, 127.9, 127.8, 107.3, 88.0, 83.4, 
79.4, 72.3, 72.0, 63.5, 55.0, 34.1, 31.9, 29.7, 29.6, 29.62, 29.5, 
29.3, 29.27, 29.1, 24.8, 22.7, 14.1;  νmax: 3034, 2915, 2849, 
1741, 1471, 1100, 758 cm
-1
. 
(b) Palladium hydroxide on activated charcoal (20% Pd(OH)2-C, 
0.0026 g, 0.15 fold by weight) was added to a stirred solution of 
7a (0.010g, 0.01 mmol) in dry CH2Cl2: MeOH (1:1, 2 mL) at 
room temperature  under hydrogen atmosphere. The reaction 
mixture was stirred for 24 h then filtered and the precipitate 
washed with CH2Cl2 (10 mL), the filtrate was evaporated and the 
residue was purified by column chromatography eluting with 
hexane/ethyl acetate (1:1) to afford the title compound as a 
colorless oil 8a (0.0079 g, 81%) [MALDI-Found  (M+Na)
+
: 
509.5, C28H54NaO6 requires: 509.3],  [] 22D +46 (c 0.10, CHCl3), 
which showed δH (500 MHz, CDCl3): 4.92 (1H, s), 4.32 – 4.29 
(2H, m), 4.22 (1H, dd, J 7.1, 3.9 Hz), 4.09 (1H, br. s), 3.90 (1H, 
br.s), 3.42 (3H, s), 2.81 – 2.67 (1H, m), 2.51 – 2.39 (1H, m), 2.38 
– 2.32 (2H, m), 1.62 (2H, dd, J 14.7, 7.3 Hz), 1.35 – 1.20 (36H, 
m), 0.89 (3H, t, J 7.0 Hz); δC (101 MHz, CDCl3): 173.5, 108.8, 
83.7, 79.8, 78.0, 63.8, 55.0, 34.1, 31.9, 29.7, 29.6, 29.5, 29.4, 
29.3, 29.2, 29.0, 24.8, 22.6, 14.1 ; νmax: br. 3500, 2917, 
2850,1739, 1464, 1100,758 cm
-1
. 
 
3.5: Methyl 2,3-di-O-benzyl-5-O-palmitoyl-α-D-Araf 8b  
(a) Cesium hydrogen carbonate  (0.19 g, 1.0 mmol) was added to 
a stirred solution of 5 (0.1 g, 0.2 mmol) and palmitic acid (0.061 
g, 0.237 mmol) in dry DMF:THF (1: 5, 5 mL) at room 
temperature and the reaction mixture was stirred at 70 ºC for two 
days. The suspension was diluted with ethyl acetate (10 mL) and 
water (10 mL). The organic layer was separated and the aqueous 
layer was re-extracted with ethyl acetate (2 × 10 mL). The 
combined organic layers were washed with water (15 mL) and 
brine (15 mL), dried, filtered and evaporated to give a thick oil 
residue. The residue was purified by column chromatography 
eluting with hexane/ethyl acetate (10:1) to give methyl 2,3-di-O-
benzyl-5-O-palmitoyl-α-D-Araf 7b (0.089 g, 76%).
25
 as a 
colorless oil [MALDI-Found  (M+Na)+ : 605.1, C36H54NaO6 
requires: 605.3], [] 22
D
+37 (c 0.10, CHCl3), which showed δH 
(500 MHz, CDCl3): 7.39 – 7.28 (10H, m), 4.95 (1H, s), 4.59 (1H, 
d, J 12.0 Hz), 4.57 (1H, d, J 11.7 Hz), 4.52 (1H, d, J 12.0 Hz), 
4.49 (1H, d, J 11.8 Hz), 4.29 (1H, dd, J 11.3, 2.9 Hz), 4.24 – 4.15 
(2H, m), 4.01 (1H, dd, J 3.0, 1.2 Hz), 3.84 (1H, dd, J 6.2, 2.9 
Hz), 3.40 (3H, s), 2.32 – 2.27 (2H, m), 1.64 – 1.54 (2H, m), 1.26 
(24H, s), 0.89 (3H, t, J 7.0 Hz);  δC (101 MHz, CDCl3): 173.6, 
137.5, 137.3, 128.4, 128.3, 127.9, 127.8, 107.3, 88.0, 83.4, 79.3, 
72.3, 72.0, 63.5, 54.9, 34.1, 31.9, 29.7, 29.68, 29.6, 29.4, 29.32, 
29.3, 29.1, 24.8, 22.7, 14.1; νmax: 3064, 3032, 2924, 2853, 1740, 
1455, 1365, 1107, 735 cm
-1
 .  
(b) Palladium hydroxide on activated charcoal (20% Pd(OH)2-C , 
0.01 g, 0.15 fold by weight ) was added  to a stirred solution of 
7b (0.06 g, 0.10 mmol) in dry CH2Cl2 : MeOH, (1:1, 2 mL) at 
room temperature  under hydrogen atmosphere. The reaction 
mixture was stirred for 24 h then filtered and the precipitate was 
washed with CH2Cl2 (10 mL), the filtrate was evaporated and the 
residue was purified by column chromatography eluting with 
hexane/ethyl acetate (1:1) to afford the title compound as a 
colorless oil 8b (0.04 g, 88%),
34
 [] 18
D
+1.2 (c 0.10, CHCl3) 
[MALDI-Found  (M+Na)
+
: 425.5, C22H42NaO6 requires: 425.2] 
which showed δH (500 MHz, CDCl3): 4.93 (1H, s), 4.33 – 4.30 
(2H, m), 4.22 (1H, dd, J 6.9, 3.9 Hz), 4.09 (1H, br. s), 3.91 (1H, 
br. s), 3.43 (3H, s), 2.35 (2H, t, J 7.6 Hz), 1.67 – 1.60 (2H, m), 
1.56 (2H, br. s), 1.36 – 1.21 (24H, m), 0.89 (3H, t, J 6.9 Hz); δC 
(101 MHz, CDCl3): 173.5, 108.8, 83.8, 79.8, 78.0, 63.8, 55.1, 
34.1, 31.9, 29.6, 29.6, 29.5, 29.4, 29.3, 29.2, 29.0, 24.8, 22.6, 
14.1 ; νmax: br. 3308, 2916, 2848, 1742, 1472, 1099, 728 cm
-1
. 
 
3.6: Methyl 5-O-oleoyl-α-D-Araf 8c 
(a) Cesium hydrogen carbonate (0.47 g, 2.42 mmol) was added to 
a stirred solution of 5 (0.26 g, 0.52 mmol) and oleic acid (0.10 g, 
0.35 mmol) in dry DMF:THF (1:5, 2 mL) at room temperature 
and the mixture was stirred at 70 ºC for two days. The suspension 
was diluted with ethyl acetate (10 mL) and water (10 mL). The 
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 7 
organic layer was separated and the aqueous layer was re-
extracted with ethyl acetate (2 × 10 mL). The combined organic 
layers were washed with water (15 mL) and brine (15 mL). The 
organic layer was dried, filtered and evaporated to give a thick oil 
residue. This was purified by column chromatography eluting 
with hexane/ethyl acetate (7:2) to afford methyl 2,3-di-O-benzyl-
5-O-oleoyl-α-D-Araf as a colorless oil 7c (0.18 g, 83%) 
[MALDI-Found  (M+Na)
+
 : 631.3, C38H56NaO6 requires : 631.4], 
[] 22
D
+45  (c 0.10, CHCl3) which showed δH (400 MHz, CDCl3):  
7.39 – 7.28 (10H, m), 5.41 – 5.30 (2H, m), 4.95 (1H, s), 4.59 
(1H, d, J 12.0 Hz), 4.57 (1H, d, J 12 Hz), 4.52 (1H, d, J 12 Hz), 
4.49 (1H, d, J 12 Hz), 4.29 (1H, dd, J 11.0, 2.5 Hz), 4.24 – 4.15 
(2H, m), 4.0 (1H, br d, J 2.1 Hz), 3.84 (1H, dd, J 6.2, 2.8 Hz), 
3.40 (3H, s), 2.30 (2H, t, J 7.6 Hz), 2.06 – 1.97 (4H, m), 1.64 – 
1.54 (4H, m), 1.28 (18H, br m), 0.89 (3H, t, J 6.8 Hz); δC (101 
MHz, CDCl3): 173.6, 137.5, 137.4, 130.0, 129.7, 128.5, 128.4, 
127.9, 107.3, 87.9, 83.3, 79.3, 72.3, 72.0, 63.5, 55.0, 34.0, 31.9, 
29.7, 29.6, 29.5, 29.3, 29.17, 29.11, 29.1, 27.25, 27.2, 24.8, 22.6, 
14.1; νmax: 3005, 3089, 3031, 2926, 2855, 1740, 1454, 1050, 735 
cm
-1
. 
(b) Boron trichloride
49
 (0.32 mL, 1M) was added to a stirred 
solution of compound (7c) (0.02 g, 0.03 mmol) in dry CH2Cl2 (2 
mL) at -78 ºC. The mixture was stirred for 2 h then quenched 
with CH2Cl2:MeOH (1:1, 2 mL) and the solvent was evaporated 
and the residue was purified by column chromatography eluting 
with hexane/ethyl acetate (1:1) to afford the title compound (7c) 
(9 mg, 64%) [Found (MALDI) (M+Na)
+
: 451.3, C24H44NaO6 
requires: 451.3], [] 18
D
 +5.0 (c 0.10, CHCl3) which showed δH 
(400 MHz, CDCl3 + few drops CD3OD): 5.35 – 5.26 (2H, m), 
4.77 (1H, d, J 4.3 Hz), 4.24 (1H, dd, J 11.7, 2.1 Hz), 4.11 – 4.05 
(1H, m), 4.02 – 3.97 (1H, m), 3.97 – 3.91 (2H, m), 3.39 (3H, s), 
2.32 (2H, t, J 7.6 Hz), 2.04 – 1.92 (4H, m), 1.65 – 1.54 (2H, m), 
1.35 – 1.15 (22H, m), 0.84 (3H, t, J 6.7 Hz); δC (101 MHz, 
CDCl3 + few drops CD3OD): 174.3, 129.96, 129.7, 102.3, 79.9, 
77.7, 75.8, 65.4, 55.2, 49.6, 49.3, 49.1, 48.9, 48.7, 34.1, 31.8, 
29.7, 29.6, 29.4, 29.2, 29.1, 29.0, 27.1, 27.09, 24.8, 22.6, 13.98; 
νmax: br. 3468, 2917, 2850, 1735, 1454, 1050, 824 cm
-1
. 
  
3.7: Methyl 5-O-stearyl-α-D-Araf  
Palladium hydroxide on activated charcoal (20% Pd(OH)2-C, 
0.012 g, 0.15 fold by weight) was added to a  stirred solution of 
7c (0.08 g, 0.13 mmol) in dry (CH2Cl2 : MeOH, 1:1, 3 mL) at 
room temperature under hydrogen atmosphere. The mixture was 
stirred for 24 h then filtered and the precipitate washed with 
CH2Cl2 (15 mL), the filtrate was evaporated and the residue was 
purified by column chromatography eluting with hexane / ethyl 
acetate (1:1) to afford the title compound as a colorless oil  
(0.045 g, 80%) [MALDI-Found (M+Na)
+
: 453.0, C24H46NaO6 
requires: 453.3];  [] 18
D
+2 (c 0.1, CHCl3); δH (400 MHz, CDCl3): 
4.92 (1H, s), 4.30 (2H, d, J 4.0 Hz), 4.21 (1H, dd, J 7.3, 3.8 Hz), 
4.17 – 4.06 (1H, m), 3.90 (1H, br d, J 10.1 Hz), 3.42 (3H, s), 2.77 
(1H, d, J 10.2 Hz), 2.52 (1H, d, J 7.9 Hz), 2.35 (2H, t, J 7.6 Hz), 
1.69 – 1.58 (2H, m), 1.34 – 1.21 (28H, m), 0.88 (3H, t, J 6.8 Hz); 
δC (101 MHz, CDCl3): 173.5, 108.8, 83.7, 79.8, 78.0, 63.8, 55.1, 
50.8, 34.1, 31.9, 29.7, 29.6, 29.6, 29.4, 29.3, 29.2, 29.05, 24.79, 
22.67, 14.10; νmax: br. 3468, 2917, 2850, 1735, 1454, 1050, 824 
cm
-1
. 
 
3.8: Methyl 5-O-(2-{(R)-1-hydroxy-18-[(1S, 2R)-2-[(17S, 18S) 
-17-methoxy-18-methylhexatriacontyl]cyclopropyl]octadecyl} 
tetracosanoate) α-D-Araf 8d 
(a) Cesium hydrogen carbonate (0.056 g, 0.288 mmol) was 
added to a solution of 5 (0.031g, 0.062 mmol) and (R)-2-{(R)-1-
hydroxy-18-[(1S,2R)-2-((17S,18S)-17-methoxy-18-
methylhexatriacontyl) cyclopropyl]octadecyl}tetracosanoic acid 
(0.051g, 0.041 mmol)
37
 in dry DMF:THF (1:5, 2 mL) at room 
temperature and the mixture was stirred at 70 ºC for two days. 
Work up as before gave methyl 2,3-di-O-benzyl-5-O-(2-{(R)-1-
hydroxy-18-[(1S,2R)-2-[(17S,18S )-17-methoxy-18-
methylhexatriacontyl]cyclopropyl]octadecyl}- tetracosanoate) α-
D- Araf 7d as a thick colorless oil (0.05 g, 77%), [Found  
(M+Na)
+
:1574.4044, C103H186NaO8  requires: 1574.4040]; [] 20D
+23 (c 0.10, CHCl3); δH (400 MHz, CDCl3): 7.39 – 7.28 (10H, 
m), 4.92 (1H, s), 4.58 (1H, d, J 12.0 Hz), 4.56 (1H, d, J 12 Hz), 
4.51 (1H, d, J 12 Hz), 4.48 (1H, d, J 12 Hz), 4.33 – 4.27 (2H, m), 
4.25 – 4.19 (1H, m), 3.99 (1H, br d, J 2.0 Hz), 3.84 (1H, dd, J 
6.4, 2.6 Hz), 3.67 – 3.59 (1H, m), 3.37 (3H, s), 3.35 (3H, s), 2.99 
– 2.94 (1H, m), 2.52 (1H, d, J 8.3 Hz), 2.43 (1H, dt, J 9.4, 5.4 
Hz), 1.72 – 1.61 (2H, m), 1.59 – 1.03 (141H, m), 0.89 (6H, t, J 
6.8 Hz), 0.86 (3H, d, J 6.9 Hz), 0.70 – 0.61 (2H, m), 0.60 – 0.53 
(1H, dt, J 4, 8 Hz), –0.33 (1H, br. q J 5.1 Hz); δC (101 MHz, 
CDCl3): 175.0, 128.5, 128.4, 127.9, 127.8, 107.2, 87.9, 85.4, 
83.7, 79.4, 72.4, 72.1, 63.5, 57.7, 54.9, 51.53, 35.52, 35.3, 32.36, 
31.9, 30.5, 30.48, 30.4, 30.3, 30.23, 30.12, 30.0, 29.98, 29.94, 
29.9, 29.86, 29.84, 29.7, 29.6, 29.5, 29.4, 29.3, 29.3, 29.26, 29.2, 
29.19, 29.1, 29.0, 29.04, 28.7, 28.67, 27.5, 27.4, 26.1, 25.7, 22.7, 
22.6, 15.7, 14.8, 14.1, 10.9; νmax: 3479, 3064, 2924, 2853, 1735, 
1494, 1455, 1100 cm
-1
. 
(b) Palladium hydroxide on activated charcoal (20%  Pd(OH)2-C 
, 0.0033 g , 0.15 fold by weight) was added to a stirred solution 
of 7d (0.022 g, 0.014 mmol) in dry CH2Cl2 : MeOH (1:1, 2 mL) 
at room temperature under hydrogen atmosphere. The mixture 
was stirred overnight; work up as before gave the title compound 
as a thick colorless oil 8d (0.016 g, 79%) [Found (M+NH4)
+
:  
1389.3550,  C89H178NO8 requires: 1389.3552];  [] 21D +28 (c 
0.10, CHCl3); δH (400 MHz, CDCl3): 4.89 (1H, s), 4.49 (1H, dd, 
J 12, 4.0 Hz), 4.35 (1H, dd, J 12, 4.1 Hz), 4.21 – 4.15 (1H, m), 
4.07 (1H, br.s), 3.98 (1H, br.s), 3.77 – 3.66 (1H, m), 3.41 (3H, s), 
3.35 (3 H, s), 3.01 – 2.92 (1H, m), 2.85 (1H, s), 2.54 – 2.36 (1H, 
ddd, J 10.1, 6.9, 5.1 Hz), 1.48 – 1.17 (144H, m), 0.89 (6H, t, J 
6.8 Hz), 0.86 (3H, d, J 6.9 Hz), 0.70 – 0.61 (2H, m), 0.61 – 0.52 
(1H, dt, J 7.9, 3.9 Hz), -0.33 (1H, br. q J  5.1 Hz); δC (101 MHz, 
CDCl3): 174.9, 108.7, 85.4, 83.6, 80.5, 78.4, 72.8, 63.2, 57.7, 
54.9, 52.3, 35.3, 35.2, 32.3, 31.9, 30.7, 30.69, 30.64, 30.62, 
30.55, 30.5, 30.4, 30.37, 30.3, 30.28, 30.2, 30.1, 30.0, 29.9, 29.8, 
29.7, 29.6, 29.57, 29.55, 29.5, 29.4, 29.3, 29.28, 29.25, 29.2, 
29.1, 29.0, 29.03, 29.0, 28.9, 28.7, 28.6, 28.5, 28.3, 27.5, 27.4, 
26.1, 25.4, 22.6, 15.7, 14.8, 14.1, 10.9; νmax: br.3435, 2918, 2850, 
1732, 1455,1100 cm
-1
. 
 
3.9: Methyl 5-O-(2-[(R)-1-hydroxy-18-[(1R ,2S)-2-[(17S,18S)-
17-methoxy-18-methylhexatriacontyl]cyclo propyl]octadecyl-
]tetracosanoate) α-D-Araf 8e 
(a) Cesium hydrogen carbonate  (0.098 g, 0.505 mmol) was 
added to a stirred solution of 5 (0.0546 g, 0.1000 mmol) and  (R)-
2-{(R)-1-hydroxy-18-[(1R,2S)-2-((17S,18S)-17-methoxy-18-
methyl-hexatriacontyl)cyclopropyl]octadecyl}tetracosanoic acid 
(0.100 g, 0.081 mmol)
37
 in dry DMF:THF (1:5, 2 mL) at room 
temperature and the reaction mixture was stirred at 70 ºC for two 
days. The suspension was diluted with ethyl acetate (10 mL) and 
water (10 mL). The organic layer was separated and the aqueous 
layer was re-extracted with ethyl acetate (2 × 10 mL). The 
combined organic layers were washed with water (15 mL) and 
brine (15 mL), then dried, filtered and evaporated to give a thick 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Tetrahedron 8 
oil residue. The residue was purified by column 
chromatography eluting with hexane/ethyl acetate (10:1) to give 
methyl 2,3-di-O-benzyl-5-O-(2-[(R)-1-hydroxy-18-[(1R,2S)-2-
[(17S,18S)-17-methoxy-18-methyl-hexatriacontyl]-
cyclopropyl]octadecyl]tetracosanoate)α-D-Araf as a colorless 
thick oil 7e (0.095 g, 75%) [Found (M+Na)
+
: 1574.4085, 
C103H186NaO8 requires: 1574.4040], [] 23D +18 (c 0.10, CHCl3), 
which showed δH (500 MHz, CDCl3): 7.38 – 7.29 (10H, m), 4.92 
(1H, s), 4.58 (1H, d, J 12 Hz), 4.56 (1H, d, J 12 Hz), 4.51 (1H, d, 
J 12 Hz), 4.48 (1H, d, J 12 Hz), 4.31 – 4.28 (2H, m), 4.24 – 4.20 
(1H, m), 3.99 (1H, dd, J 2.7, 0.9 Hz), 3.84 (1H, dd, J 6.4, 2.6 
Hz), 3.66 – 3.60 (1H, m), 3.38 (3H, s), 3.35 (3H, s), 3.00 – 2.93 
(1H, m), 2.52 (1H, br. s), 2.43 (1H, dt, J 9.1, 5.5 Hz), 1.72 – 1.61 
(2H, m), 1.60 – 1.07 (141H, m), 0.89 (6H, t, J 6.9 Hz), 0.86 (3H, 
d, J 6.8 Hz), 0.69 – 0.62 (2H, m), 0.57 (1H, dt, J 8.4, 4.1 Hz), – 
0.32 (1H, q, J 5.2 Hz); δC (101 MHz, CDCl3): 175.0, 137.5, 
137.3, 128.6, 128.5, 127.9, 127.8, 107.2, 87.9, 85.4, 83.7, 79.4, 
72.4, 72.2, 72.1, 63.5, 57.7, 54.9, 51.5, 35.5, 35.3, 32.5, 32.3, 
31.9, 31.3, 31.0, 30.9, 30.8, 30.79, 30.6, 30.58, 30.5, 30.47, 30.4, 
30.38, 30.37, 30.3, 30.29, 30.2, 30.19, 30.1, 29.9, 29.8, 29.7, 
29.6, 29.5, 29.4, 29.3, 29.2, 29.18, 29.17, 29.16, 29.15, 29.0, 
28.9, 28.8, 28.7, 28.5, 28.4, 28.3, 27.6, 27.4, 27.3, 26.9, 26.1, 
25.7, 22.6, 15.7, 14.8, 14.1, 10.9 ; νmax : 3479, 3064, 2923, 2853, 
1733, 1465, 1100, 721 cm
-1
. 
(b) Palladium hydroxide on activated charcoal (20% Pd(OH)2-C , 
0.003 g , 0.15 fold by weight) was added  to a stirred solution of 
7e (0.020 g, 0.012 mmol) in dry CH2Cl2 : MeOH (1:1, 2 mL) at 
room temperature under hydrogen atmosphere. The mixture was 
stirred overnight then filtered and the solvent was evaporated to 
give a residue; column chromatography eluting with hexane/ethyl 
acetate (1:1) gave the title compound as a colorless oil 8e (0.011 
g, 65%) [Found (M+Na)
+
: 1394.3138, C89H174NaO8 requires: 
1394.3101],  [] 16
D
 +10 (c 0.70, CHCl3);
 
δH (400 MHz, CDCl3): 
4.89 (1H, s), 4.50 (1H, dd, J 12, 3.8 Hz), 4.32 (1H, dd, J 12, 4.4 
Hz), 4.20 – 4.16 (1H, m), 4.07 (1H, d, J 5.6 Hz), 4.00 – 3.96 (1H, 
m), 3.74 – 3.64 (1H, m), 3.41 (3H, s), 3.35 (3H, s), 3.00 – 2.93 
(1H, m), 2.79 – 2.7 (2H, m), 2.48 – 2.39 (1H, m), 2.39 – 2.32 
(1H, m), 1.6 – 1.05 (143H, m), 0.89 (6H, t, J 6.8 Hz), 0.86 (3H, 
d, J 6.9 Hz), 0.69 – 0.63 (2H, m), 0.60 – 0.53 (1H, dt J ), -0.32 
(1H, br. q J 4.5 Hz);
  
δC (101 MHz, CDCl3): 174.9, 108.7, 85.4, 
83.8, 80.4, 78.4, 72.8, 63.2, 57.7, 55.0, 52.2, 35.3, 35.2, 32.3, 
31.9, 30.5, 30.2, 30.0, 29.9, 29.7, 29.68, 29.6, 29.5, 29.4, 29.3, 
28.7, 27.5, 27.4, 26.1, 25.4, 22.7, 15.7, 14.99, 14.1, 10.9; νmax: br. 
3436, 2918, 2850, 1732, 1467, 1099, 720 cm
-1
.
  
 
3.10: Methyl 5-O-(2-[(R)-1-hydroxy-18-[(1R, 2S)-2-[(17S, 18 
S)-17-methoxy-18-methylhexatriacontyl]cyclopropyl]octa- 
decyl] hexacosanoate) α-D-Araf 8f 
 
(a) Cesium hydrogen carbonate  (0.083 g, 0.428 mmol) was 
added with stirring to 5 (0.0457 g, 0.091 mmol) and (R)-2-{(R)-
1-hydroxy-18-[(1R,2S)-2-((17S,18S)-17-methoxy-18-
methylhexa- triacontyl)cyclopropyl]octadecyl}hexacosanoic acid 
(0.076 g, 0.060 mmol)
40
 in dry DMF:THF (1:5, 2 mL) at room 
temperature and the mixture was stirred at 70 ºC for two days 
then worked up as before to give methyl 2,3-di-O-benzyl-5-O-(2-
[(R)-1-hydroxy-18-[(1R,2S)-2-[(17S,18S)-17-methoxy-18-
methylhexatriacontyl]- cyclopropyl]octadecyl]hexacosanoate)α-
D-Araf 7f (0.077 g, 80%) as a thick colorless oil [Found 
(M+Na)
+
: 1602.4304, C105H190NaO8 requires: 1602.4353], [] 22D
+18 (c 0.10, CHCl3), which showed δH (400 MHz, CDCl3): 7.39 
– 7.28 (10H, m), 4.92 (1H, s), 4.58 (1H, d, J 12 Hz), 4.56 (1H, d, 
J 12 Hz), 4.51 (1H, d, J 12 Hz), 4.48 (1H, d, J 12 Hz), 4.31 – 
4.28 (2H, m), 4.26 – 4.19 (1H, m), 4.0 (1H, dd, J 5.6, 2.5 Hz), 
3.84 (1H, dd, J 6.3, 2.5 Hz), 3.68 – 3.58 (1H, m), 3.37 (3H, s), 
3.35 (3H, s), 3.00 – 2.93 (1H, m), 2.50 (1H, d, J 8.2 Hz), 2.44 
(1H, dt, J 8.7, 5.4 Hz), 1.75 – 1.56 (2H, m), 1.58 – 1.04 (145H, 
m), 0.89 (6H, t, J 6.8 Hz), 0.86 (3H, d, J 6.9 Hz), 0.70 – 0.62 
(2H, m), 0.57 (1H, dt, J 8 4 Hz), -0.32 (1H, br. q  J 5.0 Hz); δC 
(101 MHz, CDCl3): 175.0, 137.4, 137.3, 128.5, 128.4, 128.0, 
127.9, 127.89, 127.88, 127.87, 127.86, 107.2, 87.8, 85.4, 83.7, 
79.4, 72.4, 72.2, 72.1, 63.4, 57.7, 54.9, 51.5, 35.5, 35.3, 32.4, 
31.9, 30.8, 30.7, 30.67, 30.6, 30.55, 30.5, 30.45, 30.4, 30.38, 
30.37, 30.36, 30.2, 30.17, 30.16, 30.15, 30.0, 29.9, 29.8, 29.7, 
29.6, 29.5, 29.4, 29.3, 29.27, 29.26, 29.2, 29.14, 29.1, 29.07, 
29.02, 29.01, 28.94, 28.9, 28.7, 28.65, 28.6, 28.52, 28.5, 27.5, 
27.4, 26.1, 25.7, 22.6, 15.7, 14.8, 14.1, 10.9 ; νmax: br. 3522, 
3064, 2921, 2851 , 1723, 1467, 1027, 732 cm
-1
. 
(b) Palladium hydroxide on activated charcoal (20% Pd(OH)2-C, 
0.003 g, 0.15 fold by weight) was added to a stirred solution of 7f 
(0.020 g, 0.012 mmol) in dry CH2Cl2 : MeOH (1:1, 2 mL) at 
room temperature under hydrogen atmosphere. The mixture was 
stirred overnight then worked up as before to give the title 
compound as a thick colorless oil 8f (0.014 g, 76%) [Found 
(M+Na)
+
:   1422.3425, C91H178NaO8 requires: 1422.3414]; [] 21D
+10 (c 0.10, CHCl3);
 
δH (400 MHz, CDCl3): 4.89 (1H, s), 4.51 
(1H, dd, J 12, 3.9 Hz), 4.33 (1H, dd, J 12.0, 4.1 Hz), 4.21 – 4.15 
(1H, m), 4.07 (1H, br. s), 4.01 – 3.95 (1H, m), 3.75 (1H, d, J 5.3 
Hz), 3.73 – 3.66 (1H, m), 3.41 (3H, s), 3.35 (3H, s), 3.00 – 2.93 
(1H, m), 2.85 – 2.70 (2H, m), 2.50 – 2.39 (1H, m), 1.72 – 1.61 
(2H, m), 1.60 – 1.03 (145H, m), 0.89 (6H, t, J 6.8 Hz), 0.85 (3H, 
d, J 6.8 Hz), 0.70 – 0.61 (2H, m), 0.60 – 0.53 (1H, dt, J 8, 4 Hz), 
-0.33 (1H, br. q, J  5.2 Hz);
  
δC (101 MHz, CDCl3): 175.0, 108.7, 
85.5, 83.8, 80.4, 78.4, 72.8, 63.2, 57.7, 55.0, 52.2, 35.3, 35.2, 
32.3, 31.9, 30.5, 30.2, 29.9, 29.89, 29.7, 29.6, 29.6, 29.5, 29.4, 
29.3, 28.7, 27.6, 27.4, 26.1, 22.4, 22.7, 15.77, 14.8, 14.1, 10.9; 
νmax: br. 3436, 2921, 2852, 1732, 1493, 1455, 759  cm
-1
. 
 
3.11: Methyl 5-O-(2-[(1R)-1-hydroxy-16-[(1R,2S)-2-[20-
methyl-19-oxooctatriacontyl]cyclopropyl] hexadecyl] tetra-
cosanoate) α-D-Araf  8g 
(a) Cesium hydrogen carbonate (0.086 g, 0.443 mmol) was added 
to a stirred solution of 5 (0.0475 g, 0.0953 mmol) and (R)-2-{(R)-
1-hydroxy-16-[(1R,2S)-2-((S)-20-methyl-19-oxo-octatriacontyl)-
cyclopropyl]hexadecyl}tetracosanoic acid (0.077 g, 0.063 
mmol)
41
 in dry DMF:THF (1:5, 2 mL) at room temperature and 
stirred at 70 ºC for two days. Work up as before gave methyl 2,3-
di-O-benzyl-5-O-(2-[(1R)-1-hydroxy-16-[(1R,2S)-2-[20-methyl-
19-oxooctatriacontyl]cyclopropyl]hexadecyl]tetracosanoate) α-
D-Araf as a thick colorless oil 7g (0.077 g, 80%) [Found 
(M+Na)
+
: 1558.3708, C102H182NaO8 requires: 1558.3727], [] 21D
+21 (c 0.10, CHCl3); δH (400 MHz, CDCl3): 7.39 – 7.28 (10H, 
m), 4.92 (1H, s), 4.58 (1H, d, J 12.0 Hz), 4.56 (1H, d, J 12 Hz), 
4.51 (1H, d, J 12 Hz), 4.48 (1H, d, J 12 Hz), 4.32 – 4.28 (2H, m), 
4.25 – 4.19 (1H, m), 3.99 (1H, br. d, J 2.2 Hz), 3.84 (1H, dd, J 
6.4, 2.8 Hz), 3.67 – 3.59 (1H, m), 3.38 (3H, s), 2.57 – 2.47 (2H, 
m), 2.47 – 2.38 (3H, m), 1.75 – 1.09 (140H, m), 1.06 (3H, d, J 
6.9 Hz), 0.89 (6H, t, J 6.7 Hz), 0.70 – 0.62 (2H, m), 0.61 – 0.53 
(1H, dt, J 3.9, 7.9 Hz), -0.32 (1H, br. q, J  5.2 Hz); δC (101 MHz, 
CDCl3): 215.2, 175.0, 137.5, 137.3, 128.5, 128.4, 127.9, 127.9, 
127.8, 107.2, 87.8, 83.7, 79.4, 72.4, 72.1, 63.4, 54.9, 51.5, 46.3, 
41.1, 33.0, 31.9, 30.2, 29.7, 29.6, 29.6, 29.5, 29.4, 29.3, 28.7, 
27.4, 27.3, 25.7, 23.7, 22.7, 16.3, 15.7, 14.1, 10.9;  νmax: br. 3524, 
3030, 3063, 2922, 2851, 1732, 1715, 1465, 1107, 733 cm
-1
. 
(b) Palladium hydroxide on activated charcoal (20% Pd(OH)2-C, 
0.0015 g, 0.15 fold by weight) was added to a stirred solution of 
7g (0.010 g, 0.006 mmol) in dry CH2Cl2 : MeOH (1:1, 2 mL) at 
room temperature under hydrogen atmosphere. The reaction 
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 9 
mixture was stirred overnight then worked up as before to afford 
the title compound as a thick white oil 8g (0.0069 g, 63%) 
[Found  (M+Na)
+
: 1378.2788, C88H170NaO8 requires: 1378.2803], 
[] 21
D
+10.5 (c 0.10, CHCl3 + few drops of CD3OD);
  
δH (400 
MHz, CDCl3): 4.89 (1H, s), 4.51 (1H, dd, J 12, 4.0 Hz), 4.33 
(1H, dd, J 12.0, 4.1 Hz), 4.21 – 4.15 (1H, m), 4.07 (1H, br. s), 
4.02 – 3.95 (1H, m), 3.74 – 3.66 (1H, m), 3.41 (3H, s), 2.90 – 
2.71 (2H, m), 2.56 – 2.48 (1H, m), 2.48 – 2.37 (4H, m, including 
the OH), 2.23 – 1.10 (140H, m), 1.05 (3H, d, J 6.9 Hz), 0.89 (6H, 
t, J 6.8 Hz), 0.70 – 0.61 (2H, m), 0.59 – 0.53 (1H, dt, J 7.9, 3.9 
Hz), -0.33 (1H, br. q, J 5.2 Hz);
 
δC (101 MHz, CDCl3 + few drops 
of CD3OD): 215.0, 174.9, 108.7, 83.8, 80.4, 78.4, 72.8, 63.2, 
54.9, 52.1, 46.3, 41.1, 35.2, 33.0, 31.9, 30.2, 29.7, 29.6, 29.5, 
29.45, 29.4, 29.35, 29.3, 28.7, 27.4, 27.3, 25.4 23.7, 22.7, 16.36, 
15.7, 14.1, 10.9 ; νmax: br. 3436, 2918, 2850, 1731, 1708, 1467, 
1170 cm
-1
. 
 
 
3.12: Methyl 5-O-(2-[(1R)-1-hydroxy-16-[(1R,2S)-2-(20-
methyl-19-oxo- octatriacontyl)cyclopropyl]hexadecyl]- 
hexacosa-noate)-α-D-Araf 8g’ 
(a) Cesium hydrogencarbonate (0.062g, 0.319 mmol) was added 
to a stirred solution of  5  (0.048 g, 0.096 mmol) and (R)-2-{(R)-
1-hydroxy-16-[(1R,2S)-2-((S)-20-methyl-19-oxo-octatriacontyl)-
cyclopropyl]hexadecyl}hexacosanoic acid  (0.080 g, 0.064 
mmol)
42
 in dry DMF : THF (1:5, 4 mL) at room temperature and 
the mixture was stirred at 70 ºC for 2 days, then worked up and 
purified as before to afford methyl 2,3-di-O-benzyl-5-O-(2-[(1R)-
1-hydroxy-16-[(1R,2S)-2-(20-methyl-19-oxooctatriacontyl)-
cyclopropyl]hexadecyl]hexacosanoate)-α-D-Araf as a colourless 
thick oil  7g’ (72 mg, 71%) [Found (M+NH4)
+
: 1581.4467, 
C104H190NO8 requires: 1581.4486], []
23
D
  + 25 (c 0.10, CHCl3) 
which showed δH (400 MHz, CDCl3): 7.42 – 7.27 (10H, m), 4.92 
(1H, s), 4.58 (1H, d, J 12.0 Hz), 4.56 (1H, d, J 11.8 Hz), 4.50 
(1H, d, J 12.0 Hz), 4.47 (1H, d, J 11.8 Hz), 4.34 – 4.26 (2H, m), 
4.22 (1H, dt, J 4.6, 9.1 Hz), 3.99 (1H, br. d, J 2.1 Hz), 3.84 (1H, 
dd, J 2.6, 6.4 Hz), 3.68 – 3.58 (1H, m), 3.38 (3H, s), 2.56 – 2.47 
(2H, m, including OH), 2.47 – 2.37 (3H, m), 1.76 – 1.09 (144H, 
m), 1.05 (3H, d, J 6.9 Hz), 0.89 (6H, t, J 6.8 Hz), 0.70 – 0.61 
(2H, m), 0.56 (1H, dt, J 4.0, 8.0 Hz), -0.33 (1H, br. q, J 5.2 Hz); 
δC (101 MHz, CDCl3): 215.2, 175.0, 137.4, 137.2, 128.5, 128.4, 
128.0, 127.9, 127.8, 107.2, 87.8, 83.7, 79.4, 72.4, 72.1, 72.0, 
63.4, 54.9, 51.5, 46.3, 41.1, 35.5, 33.0, 31.9, 30.2, 29.7, 29.67, 
29.6, 29.57, 29.5, 29.46, 29.4, 29.3, 28.7, 27.4, 27.3, 25.8, 23.7, 
22.7, 16.4, 15.8, 14.1, 10.9; νmax: 3457, 3064, 3032, 2921, 2851, 
1717, 1678, 1466, 1101, 755, 697 cm
-1
. 
(b) Palladium hydroxide on activated charcoal (20% Pd(OH)2-C, 
0.01g, 0.15 fold by weight) was added to a stirred solution of  
compound 7g’ (0.066 g, 0.042 mmol) in dry CH2Cl2 : MeOH 
(1:1, 2 mL) at room temperature under hydrogen atmosphere. 
The mixture was worked up and purified as before to afford the 
title compound 8g’ as a colourless thick oil (39 mg, 66%) [Found 
(M+NH4)
+
: 1401.3546, C90H178NO8, requires: 1401.3547], []
23
D
 
+11 (c 0.10, CHCl3) which showed δH (400 MHz, CDCl3 + few 
drops CD3OD): 4.89 (1H, s), 4.51 (1H, dd, J 3.9, 11.9 Hz), 4.32 
(1H, dd, J 4.0, 11.9 Hz), 4.21 – 4.15 (1H, m), 4.07 (1H, br. s), 
3.98 (1H, br. d, J 1.8 Hz), 3.74 – 3.66 (1H, m), 3.41 (3H, s), 2.87 
– 2.67 (2H, m), 2.55 – 2.38 (4H, m), 1.71 – 1.12 (145H, m), 1.05 
(3H, d, J 6.9 Hz), 0.89 (6H, t, J 6.8 Hz), 0.69 – 0.61 (2H, m), 
0.56 (1H, dt, J 4.0, 8.0 Hz), -0.33 (1H, br. q, J 5.2 Hz); δC (101 
MHz, CDCl3 + few drops CD3OD): 215.4, 175.0, 108.7, 83.6, 
80.6, 78.4, 72.8, 63.2, 55.0, 52.3, 50.9, 46.3, 41.1, 35.2, 33.0, 31.9, 
30.2, 29.7, 29.65, 29.6, 29.5, 29.45, 29.41, 29.40, 29.3, 28.7, 27.4, 
27.3, 25.4, 23.7, 22.7, 16.4, 15.8, 14.1, 10.9; νmax: 3405, 2920, 2851, 
1713, 1712, 1466, 1108, 759 cm-1. 
 
3.13: Methyl 5-O-(2-{(1R)-1-hydroxy-17-[(1S, 2R)-2-[(2S)-
22-methyl-21-oxotetracontan-2-yl]cyclopropyl] 
heptadecyl}hexa- cosanoate) α-D-Araf 8h 
(b) Cesium hydrogen carbonate (0.045 g, 0.232 mmol) was added 
with stirring to 5 (0.025 g, 0.050mmol) and (R)-2-{(R)-17-[(1S,2R)-
2-((1S)-1,21-dimethyl-20-oxo-nonatriacontyl)cyclopropyl]-1-
hydroxy heptadecyl}hexacosanoic acid methyl ester (0.043 g, 0.033 
mmol)43 in dry DMF:THF (1:5, 2 mL) at room temperature and 
stirred at 70 ºC for two days, then worked up as before to give methyl 
2,3-di-O-benzyl-5-O-(2-{(1R)-1-hydroxy-17-[(1S,2R)-2-[(2S)-22-
methyl-21-oxotetra-contan-2-
yl]cyclopropyl]heptadecyl}hexacosanoate) α-D- Araf 7h as a thick 
colorless oil (0.050 g, 92%) [Found (M+Na)+:1628.4539, 
C107H192NaO8 requires: 1628.4509], [] 21D +16.8   (c 0.1, CHCl3); 
 δH 
(400 MHz, CDCl3): 7.40 – 7.27 (10H, m), 4.92 (1H, s), 4.58 (1H, d, 
J 12.0 Hz), 4.56 (1H, d, J 12 Hz), 4.53 (1H, d, J 12 Hz), 4.48 (1H, d, 
J 12 Hz), 4.33 – 4.28 (2H, m), 4.22 (1H, dt, J 10.7, 4.6 Hz), 3.99 (1 
H, br d, J 1.9 Hz), 3.84 (1H, dd, J 6.4, 2.6 Hz), 3.68 – 3.58 (1H, dt, J 
7.6, 5.2 Hz), 3.38 (3H, s), 2.58 – 2.47 (2H, m), 2.47 – 2.38 (3H, 
m), 1.72 – 1.13 (146H, m), 1.06 (3H, d, J 6.9 Hz), 0.89 (9H, 
including a triplet J 7.5 Hz), 0.72 – 0.61 (1H, m), 0.50 – 0.41 
(1H, m), 0.24 – 0.08 (3H, m); δC (101 MHz, CDCl3): 215.2, 
175.0, 137.5, 137.3, 128.5, 128.4, 128.0, 127.9, 127.8, 107.2, 
87.8, 83.7, 79.4, 72.4, 72.1, 63.5, 54.9, 51.5, 46.3, 41.1, 38.1, 
37.4, 35.5, 34.5, 33.0, 31.9, 29.7, 29.6, 29.5, 29.4, 29.3, 27.4, 
27.35, 27.3, 26.1, 25.7, 23.7, 22.7, 19.7, 18.6, 16.3, 14.1, 10.5 ; 
νmax: br. 3524, 3064, 3031, 2923, 2853, 1737, 1715, 1465, 1107, 
734 cm
-1
.  
(b) Palladium hydroxide on activated charcoal (20%  Pd(OH)2-C 
, 0.0015 g, 0.15 fold by weight) was added to a stirred solution of 
7h (0.010 g, 0.006 mmol ) in dry CH2Cl2 : MeOH (1:1, 2 mL) at 
room temperature under hydrogen atmosphere. The mixture was 
stirred overnight then worked up as before to afford the title 
compound as a thick colorless oil 8h (0.010 g, 80%) [Found  
(M+Na)
+
: 1448.3585, C93H180NaO8 requires: 1448.3570], [] 21D + 
13  (c 0.10, CHCl3); δH (400 MHz, CDCl3): 4.89 (1H, s), 4.49 
(1H, dd, J 12, 4 Hz), 4.33 (1H, dd, J 12, 4.2 Hz), 4.21 – 4.16 (1H, 
m), 4.09 (1H, d, J 6.8 Hz), 4.01 – 3.95 (1H, m), 3.75 (1H, d, J 5.4 
Hz), 3.73 – 3.65 (1H, m), 3.41 (3H, s), 2.61 – 2.47 (1H, m), 2.46 
– 2.28 (5H, m), 1.72 – 1.15 (146H, m), 1.06 (3H, d, J 6.9 Hz), 
0.89 (9H, including a triplet at 0.89 with J 7.4 Hz), 0.76 – 0.61 
(1H, m), 0.51 – 0.39 (1H, m), 0.26 – 0.05 (3H, m); δC (101 MHz, 
CDCl3): 215.3, 174.9, 108.7, 83.8, 80.4, 78.8, 78.4, 72.8, 54.9, 
52.2, 46.3, 44.5, 41.1, 38.1, 37.4, 35.2, 34.5, 33.0, 31.9, 30.0, 
29.7, 29.6, 29.5, 29.3, 27.3, 26.1, 25.4, 23.71, 22.7, 19.7, 18.6, 
16.3, 14.1, 10.5; νmax: br. 3467, 2917, 2849, 1731, 1713, 1467, 
1050,720 cm
-1
. 
 
3.14: Methyl 5-O-(2-{(R)-1-hydroxy-12-[(1S, 2R) -2-[14-[(1S, 
2R)-2-eicosylcyclopropyl]tetradecyl]cyclopropyl]dodecyl}- 
hexacosanoate) α-D-Araf 8i 
 
(a) Cesium hydrogen carbonate (0.089g, 0.46 mmol) was added 
to a stirred solution of 5 (0.049 g, 0.098 mmol) and (R)-2-((R)-1-
hydroxy-12-{(1S,2R)-2-[14-((1S,2R)-2-eicosylcyclopropyl)tetradec-
yl]cyclopropyl}dodecyl)hexacosanoic acid (0.075 g, 0.065 mmol)
37
 
in dry DMF:THF (1:5, 2 mL) at room temperature and then 
stirred at 70º C for two days. Work up as before gave methyl 2,3-
di-O-benzyl-5-O-(2-{(R)-1-hydroxy-12-[(1S,2R)-2-[14-[(1S,2R)-
2-eicosylcyclopropyl]tetradecyl]cyclopropyl]dodecyl}hexacosan-
oate) α-D-Araf 7i as a thick colorless oil (0.084 g, 87%) [Found 
(M+Na)
+
: 1486.3173, C98H174NaO7 requires: 1486.3152],  [] 21D
+31 (c 0.10, CHCl3); δH (400 MHz, CDCl3): 7.39 – 7.28 (10H, 
m), 4.92 (1H, s), 4.58 (1H, d, J 12 Hz), 4.56 (1H, d, J 12 Hz), 
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4.51 (1H, d, J 12 Hz), 4.48 (1H, d, J 12 Hz), 4.32 – 4.28 (2H, 
m), 4.25 – 4.19 (1H, m), 3.99 (1H, br d, J 2.3 Hz), 3.84 (1H, dd, 
J 6.4, 2.6 Hz), 3.68 – 3.59 (1H, m), 3.38 (3H, s), 2.52 (1H, d, J 
8.3 Hz), 2.44 (1H, dt, J 9.3, 5.5 Hz), 1.62 – 1.03 (134H, m), 0.89 
(6H, t, J 6.7 Hz), 0.72 – 0.62 (4H, m), 0.61 – 0.52 (2H, dt J 8, 4 
Hz), -0.32 (2H, br. q J  5.1 Hz); δC (101 MHz, CDCl3): 175.0, 
137.4, 137.2, 128.5, 128.4, 128.0, 127.9, 127.89, 127.8, 107.2, 
87.8, 83.7, 79.4, 72.4, 72.2, 72.1, 63.5, 54.9, 51.5, 35.5, 31.9, 
30.55, 30.5, 30.45, 30.44, 30.4, 30.35, 30.3, 30.28, 30.2, 30.18, 
30.1, 30.0, 29.9, 29.7, 29.6, 29.5, 29.4, 29.3, 29.29, 29.2, 29.1, 
29.03, 29.0, 28.7, 28.6, 27.4, 25.7, 22.68, 22.6, 15.7, 14.1, 10.9 ; 
νmax: 3479, 3065, 2989, 2919, 2849, 1733,1607, 1494, 718 cm
-1
. 
(b) Palladium hydroxide on activated charcoal (20% Pd(OH)2-C , 
0.0087 g , 0.15 fold by weight) was added to a stirred solution of 
7i (0.058g, 0.039 mmol) in dry CH2Cl2 : MeOH (1:1, 2 mL) at 
room temperature under hydrogen atmosphere. The mixture was 
stirred overnight then worked up as before to afford the title 
compound as a thick colourless oil 8i (0.040 g, 80%) [Found  
(M+Na)
+
: 1306.2201, C84H162NaO7  requires: 1306.2213], [] 23D + 
12 (c 0.10, CHCl3);
  
δH (400 MHz, CDCl3 + few drops of 
CD3OD): 4.89 (1H, s), 4.47 (1H, dd, J 11.8, 4.2 Hz), 4.37 (1H, 
dd, J 11.9, 4.1 Hz), 4.20 – 4.14 (1H, m), 4.07 (1H, br. s), 3.98 
(1H, br. s), 3.79 – 3.67 (1H, m), 3.40 (3H, s), 3.06 (2H, br. s), 
2.45 (1H, dt, J 10.1, 5.0 Hz), 1.90 – 1.83 (1H, m), 1.63 – 1.07 
(134H, m), 0.89 (6H, t, J 6.8 Hz), 0.71 – 0.61 (4H, m), 0.60 – 
0.49 (2H, dt, J 8, 4 Hz), -0.33 (2H, br. q J 5.2 Hz); δC (101 MHz, 
CDCl3): 175.0, 108.7, 83.4, 80.7, 78.4, 72.8, 63.2, 54.9, 52.4, 
35.1, 31.9, 30.4, 30.2, 30.18, 29.7, 29.68, 29.6, 29.5, 29.48, 29.4, 
29.35, 29.3, 28.7, 27.4, 25.4, 22.6, 15.7, 14.1, 10.9 ; νmax: 3436, 
390, 2918, 2850, 1733, 1467, 1455, 1050 cm
-1
. 
3.15: The ELISA assay 
Serum samples were obtained from the TDR TB Specimen 
Bank.
47  
 
ELISA were carried out on 96-well flat-bottomed polystyrene 
micro-plates.  Antigens were dissolved in hexane to give an 
antigen solution of concentration 15 µg/ml.  50 µl of this solution 
was added to each well, and the solvent was left to evaporate at 
room temperature. Control wells were coated with hexane (50 µl 
/ well) only.  Blocking was done by adding 400 µl of 0.5 % 
casein/PBS buffer (pH 7.4) to each well, and the plates were 
incubated at 25 ºC for 30 min.  The buffer was aspirated and any 
excess buffer was flicked out until the plates were dry.  Serum (1 
in 80 dilution in casein/PBS buffer) (50 µl / well) was added and 
incubated at 25 ºC for 1 h.  The plates were washed with 400 µl 
casein/PBS buffer 3 times using an automatic washer, and any 
excess buffer was flicked out onto a paper towel until dry.  
Secondary antibody (anti-human IgG (Fc specific) peroxidise 
conjugated antibody produced in goat (Aldrich) (diluted to a 
concentration of 1:2000 in casein/PBS buffer) (50 µl / well) was 
added, and incubated at 25 ºC for 30 minutes.  The plates were 
again washed 3 times with 400 µl casein/PBS buffer using an 
automatic washer, and any excess buffer was again flicked out.  
OPD substrate (50 µl / well) (o-phenylenediamine (1 mg / ml) 
and H2O2 (0.8 mg / ml) in 0.1 M citrate buffer) was then added, 
and the plates were incubated for a further 30 min at 25 ºC.  The 
colour reaction was terminated by adding 2.5 M H2SO4 (50 µl / 
well), and the absorbance was read at 492nm. 
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